MIRA INFORM REPORT

 

 

Report Date :

21.08.2013

 

IDENTIFICATION DETAILS

 

Name :

EVONIK INDUSTRIES AG

 

 

Formerly Known as :

Beteiligungs AG

 

 

Registered Office :

Rellinghauser Strasse 1-11 Essen, 45128

 

 

Country :

Germany

 

 

Financials (as on) :

31.12.2011

 

 

Date of Incorporation :

12.09.2007

 

 

Com. Reg. No.:

19474

 

 

Legal Form :

Public Subsidiary

 

 

Line of Business :

Manufacturer of plastics in primary forms

 

 

No. of Employees :

33,931

 

 

RATING & COMMENTS

 

MIRA’s Rating :

A

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Status :

Good

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Germany

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

GERMANY - ECONOMIC OVERVIEW

 

The German economy - the fifth largest economy in the world in PPP terms and Europe's largest - is a leading exporter of machinery, vehicles, chemicals, and household equipment and benefits from a highly skilled labor force. Like its Western European neighbors, Germany faces significant demographic challenges to sustained long-term growth. Low fertility rates and declining net immigration are increasing pressure on the country's social welfare system and necessitate structural reforms. Reforms launched by the government of Chancellor Gerhard SCHROEDER (1998-2005), deemed necessary to address chronically high unemployment and low average growth, contributed to strong growth in 2006 and 2007 and falling unemployment. These advances, as well as a government subsidized, reduced working hour scheme, help explain the relatively modest increase in unemployment during the 2008-09 recession - the deepest since World War II - and its decrease to 6.5% in 2012. GDP contracted 5.1% in 2009 but grew by 4.2% in 2010, and 3.0% in 2011, before dipping to 0.7% in 2012 - a reflection of low investment spending due to crisis-induced uncertainty and the decreased demand for German exports from recession-stricken periphery countries. Stimulus and stabilization efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela MERKEL's second term increased Germany's total budget deficit - including federal, state, and municipal - to 4.1% in 2010, but slower spending and higher tax revenues reduced the deficit to 0.8% in 2011. In 2012 Germany reached a budget surplus of 0.1%. A constitutional amendment approved in 2009 limits the federal government to structural deficits of no more than 0.35% of GDP per annum as of 2016 though the target was already reached in 2012. By 2014, the federal government wants to balance its budget. Following the March 2011 Fukushima nuclear disaster, Chancellor Angela Merkel announced in May 2011 that eight of the country's 17 nuclear reactors would be shut down immediately and the remaining plants would close by 2022. Germany hopes to replace nuclear power with renewable energy. Before the shutdown of the eight reactors, Germany relied on nuclear power for 23% of its electricity generating capacity and 46% of its base-load electricity production.

Source : CIA


Top of Form

Company name and address Bottom of Form

Top of Form

 

 

Evonik Industries AG

                                                                                                                                                  

 

Rellinghauser

Strasse 1-11

 

Essen, 45128

Germany

 

 

Tel:

49-20-117701

Fax:

49-20-117734

 

corporate.evonik.com  

 

Plant degussa

Rodenbacher Chaussee 4 Hanau Wolfgang, Germany

Employees:

33,931

Company Type:

Public Subsidiary

Corporate Family:

161 Companies

Ultimate Parent:

RAG-Stiftung

Traded:

XETRA:

EVK

Incorporation Date:

12-Sep-2007

Auditor:

PricewaterhouseCoopers AG

Financials in:

 USD (mil)

Fiscal Year End:

31-Dec-2012

Reporting Currency:

Euro

Annual Sales:

17,512.7  1

Net Income:

1,495.7

Total Assets:

22,023.5  2

Market Value:

18,688.9

 

(17-May-2013)

 

Operating Address                   

Paul-Baumann-Strable 1, D-45764 Marl, Germany

 

Business Description                 

 

Evonik Industries AG (Evonik) is a Germany-based company engaged in the specialty chemicals sector. It has five business segments: Consumer Health and Nutrition, Resource Efficiency, Specialty Materials, Services and Real Estate. The Consumer Health and Nutrition produces specialty chemicals, principally for applications in consumer goods, animal nutrition and pharmaceutical sectors. The Resource Efficiency segment provides solutions for environment-friendly and energy-efficient products. The Specialty Materials produces polymer materials and their preproducts, and additives. The Services segment mainly provides services for Evonik’s chemicals segments and Corporate Center, but also serves third parties. The Real Estate segment comprises Evonik's portfolio of residential real estate and a 50% stake in THS. As of December 31, 2011, the Company had a number of subsidiaries in Germany, Austria, the United Kingdom, Thailand, France, the United States, Brazil and Hong Kong, among others. For the fiscal year ended 31 December 2012, Evonik Industries AG revenues decreased 12% to EUR13.63B. Net income before extraordinary items increased 6% to EUR1.15B. Revenues reflect Revenues decrease of 6% to EUR13.63B. Net Income benefited from General Administrative Expenses decrease of 2% to EUR647M (expense), Investments Recognized at Equity increase of 9% to EUR87M (income).

          

Industry                                                                                                                                     

 

Industry

Chemicals - Plastics and Rubber

ANZSIC 2006:

1821 - Synthetic Resin and Synthetic Rubber Manufacturing

NACE 2002:

2416 - Manufacture of plastics in primary forms

NAICS 2002:

325211 - Plastics Material and Resin Manufacturing

UK SIC 2003:

2416 - Manufacture of plastics in primary forms

UK SIC 2007:

2016 - Manufacture of plastics in primary forms

US SIC 1987:

2821 - Plastics Materials, Synthetic Resins, and Nonvulcanizable Elastomers

 

 

                      

Key Executives            

   

 

Name

Title

Klaus Engel

Chairman of the Executive Board, Chief Executive Officer

Wolfgang Colberg

Member of the Executive Board, Chief Financial Officer

Guenter Adam

Member of the Supervisory Board

Thomas Wessel

Member of the Executive Board, Director of Human Resources

Oliver Luckenbach

Head of Investor Relations

   

      

Financial Summary                                                                                                                        

 

As of 31-Dec-2012

Key Ratios

Company

Industry

Current Ratio (MRQ)

1.35

1.65

Quick Ratio (MRQ)

0.95

1.15

Debt to Equity (MRQ)

0.44

0.76

Sales 5 Year Growth

-2.31

16.04

Net Profit Margin (TTM) %

8.45

11.14

Return on Assets (TTM) %

6.86

7.93

Return on Equity (TTM) %

18.10

21.28

 

 

 

 

Stock Snapshot                                    

 

Traded: XETRA: EVK

 

As of 17-May-2013

   Financials in: EUR

Recent Price

31.10

 

EPS

2.47

52 Week High

33.20

 

Price/Sales

1.06

52 Week Low

29.20

 

Price/Book

2.16

Avg. Volume (mil)

0.48

 

 

 

Market Value (mil)

14,492.60

 

 

 

 

Price % Change

Rel S&P 500%

 

 

1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7782366
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.7566

 

 

Corporate Overview

 

Location
Rellinghauser
Strasse 1-11
Essen, 45128
Germany

 

Tel:

49-20-117701

Fax:

49-20-117734

 

corporate.evonik.com

Quote Symbol - Exchange

EVK - XETRA

Sales EUR(mil):

13,629.0

Assets EUR(mil):

16,663.0

Employees:

33,931

Fiscal Year End:

31-Dec-2012

 

Industry:

Chemicals - Plastics and Rubber

Incorporation Date:

12-Sep-2007

Company Type:

Public Subsidiary

Quoted Status:

Quoted

Previous Name:

RAG Beteiligungs AG

Registered No.(DEU):

19474

 

Chairman of the Executive Board, Chief Executive Officer:

Klaus Engel

 

Industry Codes

 

ANZSIC 2006 Codes:

1821

-

Synthetic Resin and Synthetic Rubber Manufacturing

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

1813

-

Basic Inorganic Chemical Manufacturing

3323

-

Industrial and Agricultural Chemical Product Wholesaling

 

NACE 2002 Codes:

2416

-

Manufacture of plastics in primary forms

2413

-

Manufacture of other inorganic basic chemicals

5155

-

Wholesale of chemical products

2441

-

Manufacture of basic pharmaceutical products

 

NAICS 2002 Codes:

325211

-

Plastics Material and Resin Manufacturing

325411

-

Medicinal and Botanical Manufacturing

424690

-

Other Chemical and Allied Products Merchant Wholesalers

325188

-

All Other Basic Inorganic Chemical Manufacturing

 

US SIC 1987:

2821

-

Plastics Materials, Synthetic Resins, and Nonvulcanizable Elastomers

2819

-

Industrial Inorganic Chemicals, Not Elsewhere Classified

5169

-

Chemicals and Allied Products, Not Elsewhere Classified

2833

-

Medicinal Chemicals and Botanical Products

 

UK SIC 2003:

2416

-

Manufacture of plastics in primary forms

2413

-

Manufacture of other inorganic basic chemicals

5155

-

Wholesale of chemical products

2441

-

Manufacture of basic pharmaceutical products

 

UK SIC 2007:

2016

-

Manufacture of plastics in primary forms

2110

-

Manufacture of basic pharmaceutical products

4675

-

Wholesale of chemical products

2013

-

Manufacture of other inorganic basic chemicals

 

Business Description

Evonik Industries AG (Evonik) is a Germany-based company engaged in the specialty chemicals sector. It has five business segments: Consumer Health and Nutrition, Resource Efficiency, Specialty Materials, Services and Real Estate. The Consumer Health and Nutrition produces specialty chemicals, principally for applications in consumer goods, animal nutrition and pharmaceutical sectors. The Resource Efficiency segment provides solutions for environment-friendly and energy-efficient products. The Specialty Materials produces polymer materials and their preproducts, and additives. The Services segment mainly provides services for Evonik’s chemicals segments and Corporate Center, but also serves third parties. The Real Estate segment comprises Evonik's portfolio of residential real estate and a 50% stake in THS. As of December 31, 2011, the Company had a number of subsidiaries in Germany, Austria, the United Kingdom, Thailand, France, the United States, Brazil and Hong Kong, among others. For the fiscal year ended 31 December 2012, Evonik Industries AG revenues decreased 12% to EUR13.63B. Net income before extraordinary items increased 6% to EUR1.15B. Revenues reflect Revenues decrease of 6% to EUR13.63B. Net Income benefited from General Administrative Expenses decrease of 2% to EUR647M (expense), Investments Recognized at Equity increase of 9% to EUR87M (income).

 

More Business Descriptions

Chemicals, Energy and Real Estate Business Areas

 

Holding Company; Chemical Products, Energy & Real Estate

 

Evonik Industries AG is primarily engaged in manufacture of plastic tableware, kitchenware and toilet articles; and manufacture of diverse plastic products (plastic headgear, insulating fittings, parts of lighting fittings, office or school supplies, articles of apparel, fittings for furniture, statuettes, transmission and conveyor belts, etc.).

 

Plastics materials or resins

 

Evonik Industries AG (Evonik) carries out the manufacture and sale of wide range of specialty chemicals. The company specializes in the production of electricity from coal and renewable energy sources. It is also involved in the business of coal power, renewable energies, trading and real estate. Evonik is a subsidiary of RAG-Stiftung. The company's business operations are classified into five segments, namely, Consumer, Health and Nutrition; Resource Efficiency; Specialty Materials; Services; and Real Estate. The company's Consumer, Health & Nutrition (CHN) segment produces specialty chemicals, which find applications in consumer goods, animal nutrition and pharmaceutical markets. It comprises the Consumer Specialties and Health & Nutrition business units. The consumer specialties division markets chemicals to the consumer goods industry for use in cleaning agents, personal care sector and hygiene products. The Health and Nutrition division carries out the manufacture and sale of essential amino acids for animal nutrition, active ingredients and catalysts. For the fiscal year ended 2011, the company reported revenue of €4,081m from the CHN segment, reflecting an increase of 10.99% over revenue in 2010. The segment accounted for 28.4% of the company’s total revenue in 2011.The Resource Efficiency segment provides solutions for environment-friendly and energy-efficient products. It comprises the Inorganic Materials and Coatings and Additives Business Units. The Inorganic Materials division carries out the design of inorganic particles. Its products cater to the rubber and tire industry, producers of polycrystalline silicon and the coatings, printing of polycrystalline silicon and coatings and printing. Coatings and Additives unit produces functional polymers and high-quality monomer specialties for the paints and coatings, adhesives and sealants industries. For the fiscal year ended 2011, the company reported revenue of €4,045m from the Resource Efficiency segment, reflecting a decrease of 3.58% over revenue in 2010. The segment accounted for 28.1% of the company’s total revenue in 2011.Evonik's Specialty Materials produces polymer materials and their preproducts, and additives. It comprises the Performance Polymers and Advanced Intermediates Business Units. The Performance Polymers segment manufactures high-performance materials for the automotive, aviation, electronics and photovoltaic’s markets. For the fiscal year ended 2011, the company reported revenue of €4,880m from the Specialty Materials segment, reflecting a increase of 18.53% over revenue in 2010. The segment accounted for 34% of the company’s total revenue in 2011.The services segment provides site services and Evonik business services. It provides services for Evonik’s chemicals segments, corporate center and third parties. Evonik Business Services provides standardized administrative services such as IT, human resources, accounting and legal services. For the fiscal year ended 2011, the company reported revenue of €952m from the services segment, reflecting a increase of 18.85% over revenue in 2010. The segment accounted for 6.6% of the company’s total revenue in 2011.The company's Real Estate segment provides rental services to private households. For the fiscal year ended 2011, the company reported revenue of €412m from the Real Estate segment, reflecting a increase of 2.49% over revenue in 2010. The segment accounted for 2.9% of the company’s total revenue in 2011. Evonik's research and development activities are determined by the needs of the market. The company's efforts are aimed at maintaining and extending the technology leadership possessed in many areas of power plant engineering and in specialty chemicals. It has over 24,000 patents and pending patents and more than 7,500 trademarks. For the fiscal year 2011, the company invested a total of €365m, for its research and development activities. The company has manufacturing facilities in 26 countries. Geographically, the company operates in six regions, namely Asia, North America, Germany, Central and South America, Other European countries and Other. For the fiscal year ended 2011, Other European countries accounted for 29% of the company's total revenue, followed by Germany with 26%, Asia with 20%, North America with 19%, Central and South America with 4% and Other with 2% revenue. The company's key subsidiaries include Evonik Degussa GmbH, Evonik Degussa Antwerpen NV, Evonik Degussa Canada, Inc., Evonik Power Saar GmbH, Evonik Energy Services GmbH and Evonik New Energies GmbH. In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor. During the same month, Evonik signed memorandum of understanding with Government of Rostov Region to start Biolys plant in Volgodonsk through the joint venture OOO DonBioTech. In January 2013, the company invested in the Cleantech Fund III of Emerald Technology Ventures. In December 2012, the company's subsidiary, Evonik Litarion GmbH entered into business partnership with Umicore. In November 2012, the company signed a cooperation agreement with Grolman Nordic AS (Grolman). According to the agreement, Grolman will distribute the company's chemical specialties for plastics, rubber and construction in Norway, Sweden, Denmark, Iceland, Estonia, Lithuania and Latvia. In October 2012, the Evonik announced to establish a new manufacturing unit for cosmetics and consumer goods in Brazil. During the same month, the company's subsidiary Evonik Corporation formed a new company, namely, Evonik Oil & Gas Group to increase its product offerings for Oil and Gas Industry. In September 2012, the company entered into a settlement agreement with its customer MEMC Electronic Materials. According to agreement, MEMC Electronic Materials agreed to pay Evonik a €70m in full settlement of all obligations under the terminated supply agreements and inturn MEMC Electronic Materials will acquire the Evonik TCS production plant.

 

Evonik Industries AG (Evonik) is a specialty chemical manufacturing company. It operates as a subsidiaary of RAG-Stiftung. The company is also involved in the business of coal power, renewable energies, trading and real estate. The company specializes in the production of electricity from coal and renewable energy sources. Evonik focuses on engineering and consulting expertise in the design, building and operation of power plants. The company's business operations are classified into five segments, namely, Consumer, Health & Nutrition; Resource Efficiency; Specialty Materials; Services; and Real Estate. Geographically, the company operates in more than 100 countries across Africa, South America, North America, Australia, Europe and Asia. Evonik is headquartered in Essen, Germany.

 

Evonik Industries established under this name in September 2007 is still a young group. Click on the link on the right to enter our history portal. Here you can learn about the origins of Evonik Industries. Also available are a large number of articles on the history of the sites outstanding technical in-novations and the people who left their mark on the history of the company. And of course we can help you delve even deeper into the history of Evonik. Just send us an e-mail using one of the addresses on the Contacts page. For more than 50 years Corporate Archives has been providing historical information on all matters pertaining to the history of the present company and its predecessors. As a valuable memory store it preserves the expertise of many generations of employees and makes it available to those working at Evonik today. In this way Corporate Archives actively contrib-utes to creating value for the company.

 

 

Chemicals - Diversified (Major)

 

 

 

 

 

 

Financial Data

Financials in:

EUR(mil)

 

Revenue:

13,629.0

Net Income:

1,164.0

Assets:

16,663.0

Long Term Debt:

1,464.0

 

Total Liabilities:

9,945.0

 

Working Capital:

2.5

 

 

 

Date of Financial Data:

31-Dec-2012

 

1 Year Growth

-12.4%

5.5%

-1.7%

 

Market Data

Quote Symbol:

EVK

Exchange:

XETRA

Currency:

EUR

Stock Price:

31.1

Stock Price Date:

05-17-2013

52 Week Price Change %:

0.0

Market Value (mil):

14,492,600.0

 

SEDOL:

B5ZQ9D3

ISIN:

DE000EVNK013

 

Equity and Dept Distribution:

09/2007, Company name changed from RAG AG. Company has withdrawn its IPO. 07/2009, Company Re-activated.

 

 

Subsidiaries

Company

Percentage Owned

Country

Evonik Degussa Hong Kong Ltd.

100%

HONG KONG SAR

BHS Projektentwicklungs-GmbH & Co. KG

100%

GERMANY

STEAG Power Saar GmbH

 

GERMANY

Evonik Degussa Mexico S.A. de C.V.

100%

MEXICO

Evonik Pension Scheme Trustee Limited

100%

UK

Evonik Degussa Peroxide Ltd.

100%

NEW ZEALAND

Evonik Goldschmidt GmbH

100%

GERMANY

Evonik Oxeno GmbH

100%

GERMANY

Evonik Röhm GmbH

100%

GERMANY

Evonik Gorapur GmbH

100%

GERMANY

Evonik Stockhausen GmbH

100%

GERMANY

Evonik Fernwärme GmbH

100%

GERMANY

Evonik Trading GmbH

100%

GERMANY

Evonik Immobilien GmbH

100%

GERMANY

Evonik Wohnen GmbH

100%

GERMANY

Evonik Power Minerals GmbH

100%

GERMANY

STEAG-Raffinerei-Kraftwerk Sachsen-Anhalt GmbH

100%

GERMANY

Evonik Grubengas-Holding NRW GmbH

100%

GERMANY

Evonik New Energies GmbH

100%

GERMANY

Evonik Peroxygens GmbH

100%

GERMANY

Evonik Persalze GmbH

100%

GERMANY

Evonik Projekt-Beteiligung Verwaltungs-GmbH

100%

GERMANY

Evonik Risk and Insurance Services GmbH

100%

GERMANY

Evonik RohMax Additives GmbH

100%

GERMANY

Evonik Walsum 10 Kraftwerksbeteiligungsgesellschaft mbH

100%

GERMANY

Goldschmidt SKW Surfactants GmbH

100%

GERMANY

HD Ceracat GmbH

100%

GERMANY

Heinrich Schäfermeyer GmbH

100%

GERMANY

Industriepark Wolfgang GmbH

100%

GERMANY

Infracor Lager- und Speditions-GmbH

100%

GERMANY

Mönch-Kunststofftechnik GmbH

100%

GERMANY

Evonik Degussa (SEA) Pte. Ltd.

100%

SINGAPORE

Evonik Degussa (Shanghai) Co. Ltd.

100%

PEOPLE'S REPUBLIC OF CHINA

Evonik Degussa Taiwan Ltd.

100%

TAIWAN

Evonik Finance B.V.

100%

NETHERLANDS

Inspec Fine Chemicals Ltd

100%

UK

Inspec Invesco

100%

UK

Evonik Energy Services GmbH

100%

GERMANY

Evonik Cyro LLC

100%

USA

Evonik Amalgamation Ltd

100%

UK

Evonik Degussa (China) Co Ltd

100%

PEOPLE'S REPUBLIC OF CHINA

Evonik Degussa Brasil Ltda

100%

BRAZIL

Evonik Degussa Canada Inc

100%

CANADA

Evonik Degussa Corporation

100%

USA

Evonik Degussa Japan Co Ltd

100%

JAPAN

Evonik Degussa UK Holdings Ltd

100%

UK

Evonik Fibres GmbH

100%

AUSTRIA

Evonik RohMax USA Inc

100%

USA

Evonik Speciality Organics Ltd

100%

UK

NIPPON AEROSIL Co Ltd

100%

JAPAN

Iskenderun Enerji Üretim ve Ticaret Anonim Sirketi

51%

TURKEY

Elektrocieplownia Zdunska Wola Sp. z o.o.

100%

POLAND

Lünener Wohnungs- und Siedlungsgesellschaft mbH

100%

GERMANY

Rhein Lippe Wohnen GmbH

100%

GERMANY

Siedlung Niederrhein GmbH

100%

GERMANY

Walsum Immobilien GmbH

100%

GERMANY

Wohnbau Auguste Victoria GmbH

100%

GERMANY

Wohnbau Westfalen GmbH

100%

GERMANY

Wohnungsbaugesellschaft mbH "Glückauf"

100%

GERMANY

Aachener Bergmannssiedlungsgesellschaft mbH

100%

GERMANY

Evonik Chempower GmbH

100%

GERMANY

Evonik Degussa Ibérica S.A.

100%

SPAIN

Evonik Degussa India Pvt. Ltd.

100%

INDIA

Evonik Degussa International AG

100%

SWITZERLAND

Evonik Degussa Italia S.p.A.

100%

ITALY

Evonik Degussa Peroxid GmbH

100%

AUSTRIA

BK-Wolfgang-Wärme GmbH

100%

GERMANY

Asian Bleaching Earth Company Ltd

100%

THAILAND

Biomass Power Plant Ridham Limited

100%

UK

Evonik Degussa France Groupe S.A.S.

100%

FRANCE

BioKraft Karstädt GmbH

100%

GERMANY

Biomasse-Heizkraftwerk Ilmenau GmbH

100%

GERMANY

CyPlus GmbH

100%

GERMANY

Evonik Degussa Immobilien GmbH & Co. KG

100%

GERMANY

Evonik Goldschmidt Rewo GmbH

100%

GERMANY

Evonik TEGO Chemie GmbH

100%

GERMANY

OPUS Personaldienstleistungen GmbH

100%

GERMANY

R & B Industrieanlagenverwertung GmbH

100%

GERMANY

RHZ Handwerks-Zentrum GmbH

100%

GERMANY

WSA GmbH

100%

GERMANY

Colortrend Australia Pty. Ltd

100%

AUSTRALIA

AQura GmbH

100%

GERMANY

Asikos Strahlmittel GmbH

100%

GERMANY

ASTA Medica GmbH

100%

GERMANY

BHS Liegenschaften GmbH & Co. KG

100%

GERMANY

Advanced Polymer Technologies Europe GmbH

100%

GERMANY

Evonik Litarion GmbH

100%

GERMANY

Infracor GmbH

100%

GERMANY

Evonik Stockhausen LLC

100%

USA

Laporte Chemicals Ltd.

100%

UK

Laporte Industries Ltd.

100%

UK

Laporte Materials (Barrow) Ltd

100%

UK

Laporte Properties Limited

100%

UK

Peter Spence & Sons Limited

100%

UK

BHS Liegenschaften Verwaltungs-GmbH

100%

GERMANY

Cosmoferm B.V.

100%

NETHERLANDS

Degussa International Inc.

100%

USA

Degussa Re S.A.

100%

LUXEMBOURG

Evonik Aerosil France S.A.R.L.

100%

FRANCE

Evonik Australia Pty Ltd

100%

AUSTRALIA

Evonik Carbogal S.A.

100%

PORTUGAL

Power Minerals UK Holdings Limited

100%

UK

R + J Garroway Limited

100%

UK

Evonik Fermas s.r.o.

100%

SLOVAKIA

Evonik Degussa GmbH

100%

GERMANY

HVG Grünflächenmanagement GmbH

 

Germany

RÜTGERS GmbH

 

Germany

Evonik Degussa GmbH

 

Germany

RBV Verwaltungs-GmbH

 

Germany

Evonik Risk and Insurance Services GmbH

 

Germany

RAG Verkauf GmbH

 

Germany

RHZ Handwerks-Zentrum GmbH

 

Germany

Vivawest GmbH

 

Germany

Evonik Services GmbH

 

Germany

Evonik Projekt-Beteiligung Verwaltungs-GmbH

 

Germany

Evonik Projekt-Beteiligungs-GmbH & Co. KG

 

Germany

Colortrend BM

 

 

Evonik Degussa (SEA) Pte. Ltd.

 

 

 

 

 

 

Shareholders

 

 

Major Shareholders

RAG Stiftung (74.99%); CVC Capital Partners (25.01%)

 

 

 

 

Key Corporate Relationships

Auditor:

PricewaterhouseCoopers AG

Bank:

Westdeutsche Landesbank Girozentrale

 

Auditor:

PricewaterhouseCoopers AG, PricewaterhouseCoopers AG

 

 

 

 

 

 

 

 

Evonik Industries AG

 

The Strategic Initiatives report is created using technology to extract meaningful insights from analyst reports about a company's strategic projects and investments. More about Strategic Initiatives

 

Strategic Initiatives



 

Key Organizational Changes

During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum. In May 2011, the company also signed an agreement for the acquisition of Hanse chemie Group. In March 2011, the company acquired RESOMER business from Boehringer Ingelheim. Evonik has more than 300 partnerships with universities around the world.
Source:
GlobalData, April 18, 2013

 

In December 2011, the company entered into an agreement with SurModics, Inc. for the acquisition of its Pharmaceuticals business. During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum. In May 2011, the company also signed an agreement for the acquisition of Hanse chemie Group. In March 2011, the company acquired RESOMER business from Boehringer Ingelheim.
Source:
GlobalData, April 18, 2013

 

Partnerships

 

Together they give us the strength we need to remain successful in the long term as well. Our employees have played a big part in that. The development of the Evonik Group has made it clear that close and trustful collaboration with representatives of the workforce is essential for our success. We will be tackling the upcoming challenges in collaboration with them and with our shareholders. Even though economic conditions are becoming tougher, we therefore have a sound basis for continued success in the future.GlobalData uses a range of research techniques to gather and verify its information and analysis.
Source:
GlobalData, April 18, 2013

 

Our employees have played a big part in that. The development of the Evonik Group has made it clear that close and trustful collaboration with representatives of the workforce is essential for our success. We will be tackling the upcoming challenges in collaboration with them and with our shareholders. Even though economic conditions are becoming tougher, we therefore have a sound basis for continued success in the future.GlobalData uses a range of research techniques to gather and verify its information and analysis. These include primary research, in-house knowledge and expertise, proprietary databases, and secondary sources such as company websites, annual reports, SEC filings and press releases.
Source:
GlobalData, April 18, 2013

 

Within the industry, industrial paints are expected to be the major segment as a result of rising infrastructure and industrial construction spending across the world. The industrial coatings market value is projected to be around 55 billion by 2020. Therefore, Evonik could gain from its coating and additive product line, which used in construction n and industrial sectors.Strategic InitiativesAs part of its business strategy, the company establishes and nourishes collaboration and agreements with other companies to enhance the scope of its business operations and bring non-dilutive capital into the company. In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor.
Source:
GlobalData, April 18, 2013

 

In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor. In December 2011, the company entered into an agreement with SurModics, Inc. for the acquisition of its Pharmaceuticals business. During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum.
Source:
GlobalData, April 18, 2013

 

Planning

 

Overall, an investment budget of more than €6 billion has been earmarked for the period up to 2016. In Argentina we are pressing ahead with the construction of a new facility for catalysts for the production of biodiesel and in Brazil we are planning a new plant for cosmetic ingredients. Moreover, there are plans to build a new production plant for superabsorbents with partners in Saudi Arabia. While these regions are very different, our strategic goal is consistent: We aim to utilize our strong technology platforms to grow our market leadership further. We want to be even nearer to the market and work even more closely with our customers around the world.
Source:
GlobalData, April 18, 2013

 

In Argentina we are pressing ahead with the construction of a new facility for catalysts for the production of biodiesel and in Brazil we are planning a new plant for cosmetic ingredients. Moreover, there are plans to build a new production plant for superabsorbents with partners in Saudi Arabia. While these regions are very different, our strategic goal is consistent: We aim to utilize our strong technology platforms to grow our market leadership further. We want to be even nearer to the market and work even more closely with our customers around the world. Innovative capability is one of Evonik‘s strengths—and a key driver of profitable growth.
Source:
GlobalData, April 18, 2013

 

Resource Management

 

The LoI was signed in Kuala Lumpur on January 16, 2013. Petronas was represented by its COO and executive vice president of Downstream Business, Datuk Wan Zulkiflee Wan Ariffin, while Evonik was represented by its member of the executive board, Dr Dahai Yu. Dr Dahai Yu, said, "The entire project is set to mark another milestone in our growth strategy in the Asian market. This is why we’re seeking for a strong long-term strategic partner like Petronas." The partnership is expected to strengthen Petronas’s position as a key downstream petrochemical player in the region.
Source:
GlobalData, April 18, 2013

 

 

 

Strengths/Weaknesses (SWOT)



 

Helpful
to achieving the objective

Harmful
to achieving the objective

Internal Origin
(attributes of the organization)

Strengths

·        Business Operations

·        Global Footprint

·        Extensive Focus on Research and Development

Weaknesses

·        Operational Constraints

External Origin
(attributes of the environment)

Opportunities

·        Strategic Initiatives

·        Growth Opportunities in Emerging Markets

·        Expansion Initiatives

·        Growing Paint and Coatings Industry

Threats

·        Changes in Regulatory Environment

·        Foreign Currency Fluctuations

·        Highly Competitive Market

 

 

Overview

 

Evonik is one of the leading industrial groups in the world. It holds a key position in the specialty chemicals market. Evonik’s research and development activities involve approximately 2,400 people at 35 sites around the world that enables it to innovate and be a front-runner. However, operational constraints are a serious issue of concern. Nevertheless, the company has growth opportunities through growing demand for paints and coatings and its strategic expansion initiatives. However, increasing competition and changing regulations could also have a negative impact on the financial health of the company.

 

Strengths

 

Business Operations

Evonik is one of the leading industrial groups with operations around the world. It holds key market position in specialty chemicals area. The company is one of the global leaders in with chemical production facilities in 26 countries. Its business operations are grouped in five business segments, namely, Consumer, Health and Nutrition; Resource Efficiency; Specialty Materials; Services; and Real Estate. The company's Consumer, Health & Nutrition (CHN) segment manufactures specialty chemicals, which find applications in consumer goods, animal nutrition and pharmaceutical markets. The CHN segment comprises the Consumer Specialties and Health & Nutrition business units. The Resource Efficiency segment offers solutions for environment-friendly and energy-efficient products. It consists of Additives, and Inorganic Materials and Coatings Business Units. Its Specialty Materials segment produces polymer materials and their preproducts, and additives. The segment comprises the Performance Polymers and Advanced Intermediates Business Units. The services segment provides site services and Evonik business services. Under the Real Estate business segment, the company is engages in modernization, demolition and new construction activities. It involves in sale and rental of residential units, principally to private households. In January 2012, Evonik and THS merged the management of real estate properties in a newly formed joint venture, Vivawest Wohnen. Such business operations enable the company to have diverse revenue streams as well as help to identify its competitive advantage.

 

Global Footprint

Widespread geographical presence has enabled the company to cater to diverse industries worldwide. The company has broad global presence in Africa, Europe, Asia, North America, Australia and South America. Its global presence enables to make optimum use of arising growth opportunities as well as insulates the company from regulatory driven changes in individual national markets. For fiscal year 2011, the company generated €3,784 million from Germany region, which has accounted for 26% of the company’s total revenue followed by, USA, € 2,395 m (16.4%); China, € 829 m (5.7%); Switzerland, € 756 million (5.2%); France € 511 m (3.5%); Netherlands, €487m (3.3%); Italy, € 428m (2.9%); Japan €427m (2.9%); and other countries, €4,923m (33.8%). The company’s global presence provides huge market potential for its products and services. It enables the company to expand its offerings and secure new contracts, acquisitions and joint ventures, which will generate additional revenues and thus will contribute to its growth. Further, global presence also reduces the impact of market volatility and provides economic stability to the company.

 

Extensive Focus on Research and Development

The company is principally involved in research and development activities to attain new heights in business operations. Evonik’s research and development work in the chemical business area involves approximately 2,400 people at 35 sites around the world. During the fiscal year 2011, the company invested around €365m in R&D activities, as compared to €338m in 2010. Evonik’s chemicals research focuses on the development of successful and established products and also at building new high-tech activities outside the company’s established business portfolio. In 2011, the company generated sales of €1.9 billion through new products and applications. The company spent approximately 40% of R&D expenses on new product development, followed by new technology platforms (20%); improved applications for established products (10%); improved production processes for established products (25%); and others (5%). Its current portfolio of patents and pending patents include more than 24,000, and it has more than 75,000 registered and pending trademarks. Evonik works in association with universities through more 300 partnerships. Such, strong research and development focus and broad patent portfolio enables the company to offer innovative products and solutions and maintain a competitive edge over its competitors.

 

 

Weaknesses

 

Operational Constraints

Operational risk may occur due to capital investments, damage of property, raw material procurement and loss of reputation. The company’s operational facilities are decentralized and are managed through a network of geographically dispersed management personnel. Any disruption, unanticipated expense or operational failure related to this process could negatively impact the company’s facilities operations. In April 2012, a fire accident occurred at the CDT plant located in Marl Chemicals Park. The CDT plant offers cyclododecatriene, which serves as a material in plastics manufacturing. As a result of fire accident, the company incurred property damages as well as lost two employees. It also adversely affected the business of VESTAMID, VESTAMELT, VESTOSINT, and VESTENAMER product ranges. Such fire accidents and operational failure could affect the operational and financial performance e of the company.

 

 

Opportunities

 

Strategic Initiatives

As part of its business strategy, the company establishes and nourishes collaboration and agreements with other companies to enhance the scope of its business operations and bring non-dilutive capital into the company. In February 2013, the company’s subsidiary CyPlus GmbH signed joint venture agreement with Grupo Idesa S.A de C.V., a Mexico based company for the construction of a sodium cyanide plant in Coatzacoalcos, Mexico. In January 2013, the company signed letter of intent with Petronas to jointly develop production facilities related to hydrogen peroxide, C4 co-monomer and oxo-products within PETRONAS’ Refinery & Petrochemical Integrated Development (RAPID) project in Pengerang, Johor. In December 2011, the company entered into an agreement with SurModics, Inc. for the acquisition of its Pharmaceuticals business. During the same month, the company acquired the Kemira’s hydrogen peroxide facility in Maitland, Ontario, Canada. Through this acquisition, the company plans to increase its hydrogen peroxide production capacity in North America by 44,000 metric tons per annum. In May 2011, the company also signed an agreement for the acquisition of Hanse chemie Group. In March 2011, the company acquired RESOMER business from Boehringer Ingelheim. Evonik has more than 300 partnerships with universities around the world. Apart from acquisitions in its core business, the company also divested its loss making businesses. In April 2012, the sold its global colorants business to Arsenal Capital Partners. In August 2011, the company sold its subsidiary, namely, Evonik Lynchem Co., Ltd to Dalian Kionge Group Co., Ltd. It also divested its carbon black business and sold to Kinove German Bidco GmbH. Such initiatives will strengthen the company’s competitive market position as well as enhance its global presence.

 

Growth Opportunities in Emerging Markets

The company could benefit through its presence in the emerging markets, which have created ample opportunities for the chemical industry over the past decade. Strong growth is expected in the emerging countries of Asia-Pacific, Africa, the Middle East, Eastern Europe and Latin America. Although the economic crisis has dampened the growth of the chemicals industry in the recent past, it continues to grow at a positive rate compared to the developed countries of Europe and North America. According to the American Chemistry Council (ACC) estimates, the demand for chemicals in emerging markets is expected to increase as compared to 2011. China is expected to grow strongly, India, Africa, Latin America and other emerging markets will continue to expand in 2012. The demand is expected to increase in specialty chemicals, consumer products, and agricultural chemicals. The overall output is expected to grow by 2.3% in 2012, 4.3% in 2013, and 4.7% in 2014. These countries are set to grow even further and lead the world as major producers of chemicals. Thus, the company could benefit by expanding its presence in the emerging markets.

 

 

Expansion Initiatives

The company focuses on product and capacity expansion activity for tapping new markets and customers. In January 2013, the company expanding its market position in C4-based products and investing in the expansion of its production facilities. The company’s 1-butene capacity in Marl Chemical Park will be expanded by 75,000 tons; production of butadiene will be expanded by 100,000 tons in Antwerp, Belgium; and MTBE capacity in Marl and Antwerp will be expanded 150,000 tons. During the same month, STOKO Professional Skin Care, the Europe’s leading manufacturers of skin protection launched new red series skin care line products into the market. In October 2012, the Evonik announced to establish a new manufacturing unit for cosmetics and consumer goods in Brazil. This expansion initiative enables the company to expand global Consumer Specialties production network. In August 2012, the company started construction of methionine complex in Singapore to expand its capacity by 580,000 metric tons. It also announced to construct production facilities for feed amino acid L-lysine in Brazil and Russia. This allows the company to significantly expand its market position and competitive standing for the feed amino acid L-lysine. In April 2012, the company launched SPHINGOKINE, unique short-chain ceramide which stimulates the cross-talk between cells throughout the skin. It also introduced a new matting agent coil, sheet as well as decorative and industrial coatings. The company launched a comprehensive acrylic lens package known as PLEXIGLAS Solar Pre-fab lens panels that incorporate specialty PMMA molding compounds and sheet products for solar applications. Evonik also introduced a wetting and dispersing additive for curable coatings and printing inks. Furthermore, the company also launched world's strongest silicone and solvent-free deaerator for EP Floor coatings. In March 2012, the company offered a skin vitalizer of pentacyclic triterpenes under the brand TEGO Arjuna. In January 2011, the company introduced a barrier film for the protection of flexible photovoltaics. Such expansion initiatives give an opportunity for the company to increase its revenues and market reach.

 

Growing Paint and Coatings Industry

Through Coatings & Additives business, the company serves coatings, printing inks, and the adhesive and sealing compounds industries across the world. It offers product such as colorants, crosslinkers coating and adhesive resins, coating additives and oil additives. Paints and coating industry is witnessing substantial growth as a result of growing infrastructure industry. According to industry estimates, the worldwide demand for paint and coatings is expected to increase 5.4 % annually through 2015 to 45.5 million metric tons, with a total value of approximately $140 billion. The Asia Pacific is estimated to be the key market for consumer of paints and coatings. Within the industry, industrial paints are expected to be the major segment as a result of rising infrastructure and industrial construction spending across the world. The industrial coatings market value is projected to be around 55 billion by 2020. Therefore, Evonik could gain from its coating and additive product line, which used in construction n and industrial sectors.

 

 

Threats

 

Changes in Regulatory Environment

Evonik could be affected by the environmental regulations governing the global chemical industry. REACH (Registration Evaluation and Authorization of Chemicals) is an example of the stringent environmental regulations that are set to affect chemical producers. REACH regulates products manufactured and marketed in Europe. Phased over a period of 11 years, the regulation mandates all companies to develop and submit dossiers containing datasets about their chemical products and detail their potential impact and risk on environment. This will prove to be a challenge while launching new products as it is a time-consuming and expensive process. It may also result in phasing out many existing chemicals from the market, which may be regarded as toxic and hazardous. REACH directly applies to over 30,000 different chemical substances that are produced or sold in Europe and its implementation is expected to cost European chemical industry about USD 3 billion. Other countries too are expected to model their regulations after REACH. The US has already started implementing similar regulations with the reform of Toxic Substances Control Act. China has its own version of RoHS (Restriction of Hazardous Substances), which restricts the use of certain chemicals in the market. Also, environmental initiatives such as global responsible care and UN Global Compact could also impact the company’s business operations. Such regulations are set to get tightened in the coming years, affecting both the existing and new products.

 

Foreign Currency Fluctuations

As a global specialty chemical company, the company operates in more than 26 countries across the world. The robust international operations of the company increased its exposure to foreign currency fluctuations. Evonik has market presence throughout the world holding assets and liabilities sin foreign currencies. It transacts business in Chinese Renminbi, British Pound Sterling, Japanese Yen, US dollar, Swiss franc and Brazilian Real. However, the functional currency of the company’s operations is the EURO. The company makes efforts to mitigate risks through foreign currency hedging. However, hedging activities may not offset more than a portion of the adverse financial impact resulting from unfavorable movement in foreign currency exchange rates. Such fluctuations in currency would negatively impact the overall financial health of the company.

 

Highly Competitive Market

Increased competition may force the company to reduce its prices, which could negatively affect its margins. Evonik operates in a highly competitive chemical industry. The key competitive factors include product price, quality, distribution, innovation, skilled staff, application and others. Its key competitors include BASF SE, The Dow Chemical Company, Exxon Mobil Corporation, BASF, Clariant Chemicals and others. The company operates in a progressively more complex and challenging chemical marketplace whose dynamics is ever-changing. Technological advances by any player in the market could render its present or future products obsolete or uneconomical. The existing market includes companies of varying sizes; some more specialized than the company with respect to particular chemicals, and some with greater financial resources than the company.

 

 

Corporate Structure News

 

Total Corporate Family Members: 161
           

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

RAG-Stiftung

Parent

Essen, Nordrhein-Westfalen

Germany

Public Sector and Government

4,317.2

30

Evonik Industries AG

Subsidiary

Essen

Germany

Chemicals - Plastics and Rubber

17,512.7

33,931

Evonik Degussa GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Chemical Manufacturing

6,601.9

38,000

Evonik Degussa Corporation

Subsidiary

Parsippany, NJ

United States

Chemical Manufacturing

 

33,000

Evonik Degussa Corp. - Mobile

Facility

Theodore, AL

United States

Chemical Manufacturing

254.7

800

Evonik Corp

Branch

Theodore, AL

United States

Chemical Manufacturing

56.9

700

Evonik Degussa - Birmingham Labs

Division

Birmingham, AL

United States

Business Services

 

90

Evonik Corp

Branch

Blair, NE

United States

Chemical Manufacturing

79.3

86

Orion Engineered Carbons

Subsidiary

Borger, TX

United States

Chemical Manufacturing

262.9

80

Evonik Goldschmidt Corp

Branch

Janesville, WI

United States

Chemical Manufacturing

58.3

76

Evonik Corp

Branch

Humble, TX

United States

Chemical Manufacturing

91.1

60

Evonik Corp

Branch

Birmingham, AL

United States

Chemical Manufacturing

56.9

60

Evonik Corp

Branch

Burr Ridge, IL

United States

Chemical Manufacturing

53.3

60

Evonik Corp

Branch

Lake Forest, CA

United States

Chemical Manufacturing

46.5

60

Evonik Oil Additives USA Inc

Subsidiary

Horsham, PA

United States

Chemical Manufacturing

 

60

Evonik Oil Additives USA

Branch

Deer Park, TX

United States

Chemical Manufacturing

83.5

55

Evonik Degussa Corp. - Lockland

Facility

Cincinnati, OH

United States

Chemical Manufacturing

143.3

50

Orion Engineered Carbons LLC

Branch

Orange, TX

United States

Chemical Manufacturing

89.1

50

Evonik Corp

Branch

Calvert City, KY

United States

Chemical Manufacturing

66.1

50

Evonik Corp

Branch

Chester, PA

United States

Chemical Manufacturing

41.3

50

Cyanco Company

Subsidiary

Winnemucca, NV

United States

Chemical Manufacturing

9.9

50

Evonik Corp

Branch

Waterford, NY

United States

Chemical Manufacturing

24.4

35

Evonik Corp

Branch

Kennesaw, GA

United States

Chemical Manufacturing

16.0

20

Orion Engineered Carbons LLC

Branch

Franklin, LA

United States

Chemical Manufacturing

22.3

6

Orion Engineered Carbon

Subsidiary

Canton, OH

United States

Chemical Manufacturing

14.6

6

Orion Engineered Carbons

Subsidiary

Baytown, TX

United States

Chemical Manufacturing

10.7

6

Evonik Corp

Branch

Piscataway, NJ

United States

Chemical Manufacturing

2.6

3

Evonik Corp

Branch

Vernon Hills, IL

United States

Chemical Manufacturing

1.8

2

Degussa International Inc

Branch

Newark, DE

United States

Chemical Manufacturing

1.7

1

Evonik Foams Inc

Subsidiary

Allen, TX

United States

Chemical Manufacturing

12.9

 

Evonik Foams Inc

Branch

Magnolia, AR

United States

Chemical Manufacturing

28.6

38

Infracor GmbH

Subsidiary

Marl, Nordrhein-Westfalen

Germany

Business Services

1,367.7

3,280

Hüls Service GmbH

Subsidiary

Marl, Nordrhein-Westfalen

Germany

Restaurants

 

143

Evonik Röhm GmbH

Subsidiary

Darmstadt, Hessen

Germany

Chemicals - Plastics and Rubber

1,687.4

3,000

Evonik Oil Additives GmbH

Subsidiary

Darmstadt, Hessen

Germany

Chemical Manufacturing

276.8

170

Evonik Rohmax Asia Pacific Pte Ltd

Subsidiary

Singapore

Singapore

Chemical Manufacturing

141.5

90

Evonik Oil Additives

Subsidiary

Lauterbourg

France

Chemical Manufacturing

72.0

34

Evonik Forhouse Optical Polymers Corp.

Subsidiary

Taichung City

Taiwan

Chemicals - Plastics and Rubber

 

50

Mönch-Kunststofftechnik GmbH

Subsidiary

Bad König, Hessen

Germany

Fabricated Plastic and Rubber

 

22

Destek Ooo

Subsidiary

Podolsk G.

Russian Federation

Fabricated Plastic and Rubber

25.8

 

Rohm America LLC

Subsidiary

Piscataway, NJ

United States

Chemical Manufacturing

 

 

Evonik Degussa GmbH - Coatings & Additives, Hanau

Unit

Hanau

Germany

Chemicals - Plastics and Rubber

 

1,700

Evonik Goldschmidt GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Chemical Manufacturing

746.8

1,450

Evonik TEGO Chemie GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Chemical Manufacturing

208.6

240

Evonik Goldschmidt Corporation

Subsidiary

Hopewell, VA

United States

Chemical Manufacturing

 

200

Evonik Goldschmidt Corp

Branch

Mapleton, IL

United States

Chemical Manufacturing

12.4

14

Evonik Hanse GmbH

Subsidiary

Geesthacht, Schleswig-Holstein

Germany

Fabricated Plastic and Rubber

36.2

62

Evonik Gorapur GmbH

Subsidiary

Wittenburg, Mecklenburg-Vorpommern

Germany

Chemical Manufacturing

 

32

Goldschmidt Benelux

Subsidiary

Bruxelles

Belgium

Chemical Manufacturing

0.0

7

Cosmoferm B.V.

Subsidiary

Delft

Netherlands

Personal and Household Products

 

5

Evonik Degussa Antwerpen

Subsidiary

Lillo

Belgium

Chemical Manufacturing

678.4

1,046

Industriepark Wolfgang GmbH

Subsidiary

Hanau, Hessen

Germany

Business Services

201.9

955

Evonik Cyro LLC

Subsidiary

Parsippany, NJ

United States

Chemicals - Plastics and Rubber

 

700

Evonik Cyro LLC

Branch

Sanford, ME

United States

Chemical Manufacturing

38.1

340

Evonik Cyro LLC

Branch

Osceola, AR

United States

Chemical Manufacturing

45.1

80

Evonik Cyro LLC

Branch

San Ramon, CA

United States

Chemical Manufacturing

2.3

3

Evonik Cyro LLC

Branch

Olathe, KS

United States

Chemical Manufacturing

2.0

2

Evonik Oxeno GmbH

Subsidiary

Marl, Nordrhein-Westfalen

Germany

Chemical Manufacturing

 

418

Evonik Khimiya Ooo

Subsidiary

Moscow

Russian Federation

Engineering Consultants

35.0

369

Evonik Degussa Brazil Ltda.

Subsidiary

São Paulo, SP

Brazil

Chemicals - Plastics and Rubber

436.3

320

Evonik Rexim SAS

Subsidiary

Ham

France

Biotechnology and Drugs

60.3

261

Korea Carbon Black Co., Ltd.

Subsidiary

Incheon

Korea, Republic of

Chemical Manufacturing

 

250

AQura GmbH

Subsidiary

Hanau, Hessen

Germany

Personal Services

 

220

Evonik Degussa Taiwan Ltd

Subsidiary

Taipei

Taiwan

Chemical Manufacturing

 

200

Evonik Degussa Gmbh

Branch

Münchsmünster, Bayern

Germany

Chemical Manufacturing

 

183

Evonik Degussa International AG

Subsidiary

Zürich

Switzerland

Chemical Manufacturing

12,413.7

180

Evonik Agroferm Fermentációipari Zrt

Subsidiary

Kaba

Hungary

Chemical Manufacturing

58.0

152

Evonik Technochemie GmbH

Subsidiary

Dossenheim, Baden-Württemberg

Germany

Chemical Manufacturing

59.9

145

Insilco Ltd.

Subsidiary

Gurgaon, Haryana

India

Chemical Manufacturing

15.2

145

Egesil Kimya Sanayi Ve Ticaret A S

Subsidiary

Istanbul (Europe)

Turkey

Chemical Manufacturing

52.4

136

Evonik Litarion GmbH

Subsidiary

Kamenz, Sachsen

Germany

Miscellaneous Capital Goods

10.5

126

Evonik Degussa Peroxid GmbH

Subsidiary

Weissenstein

Austria

Chemical Manufacturing

42.2

101

Evonik (SEA) Pte Ltd

Subsidiary

Singapore

Singapore

Chemical Manufacturing

 

100

Evonik United Silica Industrial Ltd.

Subsidiary

Tayuan Hsiang, Taoyuan

Taiwan

Chemical Manufacturing

 

100

Evonik Degussa Italia s.p.a.

Subsidiary

Ravenna

Italy

Chemical Manufacturing

 

99

Evonik Indonesia, Pt

Subsidiary

Bekasi, West Java

Indonesia

Chemical Manufacturing

9.7

74

Evonik Degussa Ibérica, S.A.

Subsidiary

Granollers, Barcelona

Spain

Chemical Manufacturing

65.2

67

Evonik Degussa Argentina S.A.

Subsidiary

Buenos Aires

Argentina

Electronic Instruments and Controls

21.8

40

CyPlus GmbH

Subsidiary

Hanau, Hessen

Germany

Chemical Manufacturing

98.4

57

Evonik Silquimica Sa

Subsidiary

Lantaron, Alava

Spain

Chemical Manufacturing

23.9

57

Degussa Brasil Ltda

Subsidiary

Sao Paulo, Sao Paulo

Brazil

Chemical Manufacturing

289.0

50

Evonik Degussa Korea Ltd.

Subsidiary

Inchon, Inchon

Korea, Republic of

Chemical Manufacturing

34.8

49

Evonik Degussa Canada Inc.

Subsidiary

Brampton, ON

Canada

Chemical Manufacturing

 

35

Evonik Degussa Ticaret Ltd Sti

Subsidiary

Istanbul (Anatolia)

Turkey

Chemical Manufacturing

 

29

Evonik Degussa UK Services Limited

Subsidiary

Milton Keynes

United Kingdom

Chemical Manufacturing

 

20

Evonik Degussa Praha s.r.o.

Subsidiary

Prague

Czech Republic

Chemical Manufacturing

 

16

Evonik Degussa Hong Kong Ltd

Subsidiary

Hong Kong

Hong Kong

Chemical Manufacturing

 

15

JSSi GmbH

Subsidiary

Freiberg, Sachsen

Germany

Metal Mining

26.3

5

Evonik Degussa Croatia d.o.o.

Subsidiary

Zagreb

Croatia

Chemical Manufacturing

 

5

Studiengesellschaft Kohle mit beschränkter Haftung

Subsidiary

Mülheim An Der Ruhr, Nordrhein-Westfalen

Germany

Biotechnology and Drugs

 

2

Goldschmidt SKW Surfactants GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Commercial Banks

 

2

Evonik Peroxygens Holding GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Personal and Household Products

 

2

Evonik Degussa Japan Co. Ltd.

Subsidiary

Osaka

Japan

Chemical Manufacturing

163.0

 

Insilco Limited

Subsidiary

New Delhi, Delhi

India

Chemical Manufacturing

13.8

 

Insilco Ltd

Branch

Gurgaon

India

Chemical Manufacturing

15.2

145

Evonik Degussa Immobilien Gmbh & Co. Kg

Subsidiary

Marl, Nordrhein-Westfalen

Germany

Real Estate Operations

4.8

 

Westgas GmbH

Subsidiary

Marl, Nordrhein-Westfalen

Germany

Commercial Banks

 

4

Degussa Skw Co

Subsidiary

Milton Keynes

United Kingdom

Business Services

 

 

Evonik Degussa UK Holdings Ltd.

Subsidiary

Milton Keynes

United Kingdom

Business Services

 

13

Evonik Speciality Organics Ltd.

Subsidiary

Milton Keynes

United Kingdom

Business Services

 

 

Evonik Amalgamation Ltd.

Subsidiary

Milton Keynes

United Kingdom

Business Services

 

 

Evonik Membrane Extraction Technology Ltd.

Subsidiary

Wembley

United Kingdom

Personal Services

1.7

16

Egl Ltd.

Subsidiary

Bristol

United Kingdom

Commercial Banks

 

1

Laporte Industries Ltd.

Subsidiary

Milton Keynes

United Kingdom

Chemical Manufacturing

 

 

Laporte Chemicals Ltd.

Subsidiary

Milton Keynes

United Kingdom

Commercial Banks

 

 

Laporte (Dl) Ltd.

Subsidiary

London

United Kingdom

Nonclassifiable Industries

 

 

Laporte Nederland (Holding) B.V.

Subsidiary

Amsterdam Zuidoost, Noord-Holland

Netherlands

Miscellaneous Financial Services

 

 

Laporte Organisation Ltd.

Subsidiary

Luton

United Kingdom

Commercial Banks

 

 

Evonik Pension Scheme Trustee Ltd.

Subsidiary

Milton Keynes

United Kingdom

Investment Services

 

 

Evonik Industries Greater China

Subsidiary

Beijing

China

Chemical Manufacturing

 

 

Degussa Homogeneous Catalysts

Subsidiary

Hanau

Germany

Chemical Manufacturing

 

 

Evonik Degussa Africa (Pty) Ltd

Subsidiary

Midrand, Gauteng

South Africa

Chemical Manufacturing

 

 

Evonik Degussa Gmbh

Branch

Herne, Nordrhein-Westfalen

Germany

Chemical Manufacturing

 

 

RÜTGERS GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Commercial Banks

 

10,928

RÜTGERS Dienstleistungs-GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Business Services

2.5

125

RÜTGERS Rail Verwaltungs GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Auto and Truck Parts

 

3

Evonik Stockhausen, LLC

Subsidiary

Greensboro, NC

United States

Chemical Manufacturing

55.8

3,600

Evonik Stockhausen, LLC - Garyville

Subsidiary

Garyville, LA

United States

Chemical Manufacturing

190.0

62

Evonik Services GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Commercial Banks

 

2,000

Evonik Industries AG - Feed Additives

Unit

Hanau

Germany

Food Processing

654.9

1,700

Evonik Industries AG - Krefeld Plant

Facility

Krefeld

Germany

Chemical Manufacturing

 

1,000

HVG Grünflächenmanagement GmbH

Subsidiary

Gelsenkirchen, Nordrhein-Westfalen

Germany

Personal Services

42.1

350

RHZ Handwerks-Zentrum GmbH

Subsidiary

Gelsenkirchen, Nordrhein-Westfalen

Germany

Construction Services

31.1

280

Evonik Fermas s.r.o.

Subsidiary

Slovenská L'upca

Slovakia

Chemical Manufacturing

58.6

250

RAG Verkauf GmbH

Subsidiary

Herne, Nordrhein-Westfalen

Germany

Chemical Manufacturing

265.0

90

Evonik Sumi Asih, Pt

Subsidiary

Bekasi, West Java

Indonesia

Chemical Manufacturing

 

60

Evonik Risk and Insurance Service GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Miscellaneous Financial Services

15.6

40

MB Kroger Greifertechnik GmbH Co. & KG

Subsidiary

Sonsbeck, Nordrhein-Westfalen

Germany

Miscellaneous Capital Goods

 

40

RBV Verwaltungs-GmbH

Subsidiary

Marl, Nordrhein-Westfalen

Germany

Commercial Banks

 

3

R & B Industrieanlagenverwertung GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Construction Services

 

2

RCIV Vermögensverwaltungs-GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Consumer Financial Services

 

1

Knipping System-Technik GmbH

Subsidiary

Halle, Saale

Germany

Construction - Supplies and Fixtures

 

2

Evonik Projekt-Beteiligungs-GmbH & Co. KG

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Commercial Banks

 

 

Evonik Industries Ag

Branch

Darmstadt, Hessen

Germany

Chemicals - Plastics and Rubber

 

 

RAG Aktiengesellschaft

Subsidiary

Herne, Nordrhein-Westfalen

Germany

Coal

3,610.9

21,458

RAG Deutsche Steinkohle AG

Subsidiary

Herne, Nordrhein-Westfalen

Germany

Miscellaneous Financial Services

 

24,000

RAG Anthrazit Ibbenbüren GmbH

Subsidiary

Ibbenbüren, Nordrhein-Westfalen

Germany

Coal

502.7

2,450

Evonik Goldschmidt Rewo GmbH

Subsidiary

Steinau, Hessen

Germany

Personal and Household Products

142.8

216

Evonik Immobilien GmbH

Subsidiary

Gelsenkirchen, Nordrhein-Westfalen

Germany

Investment Services

574.8

70

Auguste Victoria GmbH

Subsidiary

Marl, Nordrhein-Westfalen

Germany

Construction Services

37.9

3,000

Rhein Lippe Wohnen GmbH

Subsidiary

Duisburg, Nordrhein-Westfalen

Germany

Real Estate Operations

60.0

145

Siedlung Niederrhein GmbH

Subsidiary

Dinslaken, Nordrhein-Westfalen

Germany

Construction Services

 

3

Wohnungsbaugesellschaft mit beschränkter Haftung Glückauf

Subsidiary

Moers, Nordrhein-Westfalen

Germany

Construction Services

20.0

111

EBV Gesellschaft mit beschränkter Haftung

Subsidiary

Hückelhoven, Nordrhein-Westfalen

Germany

Construction Services

23.1

41

Aachener Bergmannssiedlungsges. Mbh

Subsidiary

Hückelhoven, Nordrhein-Westfalen

Germany

Real Estate Operations

5.9

19

Heinrich Schäfermeyer GmbH

Subsidiary

Hückelhoven, Nordrhein-Westfalen

Germany

Real Estate Operations

 

5

SJ Brikett- und Extrazitfabriken GmbH

Subsidiary

Hückelhoven, Nordrhein-Westfalen

Germany

Oil and Gas Operations

 

2

EBV GmbH

Subsidiary

Essen

Germany

Real Estate Operations

 

20

Wohnbau Westfalen GmbH

Subsidiary

Dortmund, Nordrhein-Westfalen

Germany

Real Estate Operations

41.4

3

Lünener Wohnungs- und Siedlungsgesellschaft mit beschränkter Haftung

Subsidiary

Lünen, Nordrhein-Westfalen

Germany

Business Services

 

5

Bauverein Glückauf GmbH

Subsidiary

Ahlen, Nordrhein-Westfalen

Germany

Construction Services

 

 

REMONDIS Industrie Service Süd GmbH & Co. KG.

Subsidiary

Rastatt, Baden-Württemberg

Germany

Trucking

 

49

Ege Kimya Sanayi ve Ticaret AS

Joint Venture

Istanbul

Turkey

Chemical Manufacturing

 

 

Polifen Kimya Sanayii Ve Ticaret A S

Subsidiary

Istanbul (Europe)

Turkey

Chemicals - Plastics and Rubber

 

140

Steag State Power Inc.

Subsidiary

Makati

Philippines

Electric Utilities

 

 

RAG Montan Immobilien GmbH

Subsidiary

Essen, Nordrhein-Westfalen

Germany

Real Estate Operations

71.6

356

Evonik Carbon Black Nederland B.V.

Subsidiary

Amsterdam Zuidoost, Noord-Holland

Netherlands

Chemical Manufacturing

7.9

99

Evonik Degussa Italia SpA

Subsidiary

Pandino, Cremona

Italy

Chemicals - Plastics and Rubber

43.5

83

Aerosil France

Subsidiary

Salaise Sur Sanne

France

Chemical Manufacturing

 

34

Evonik Degussa Africa (Pty) Ltd

Subsidiary

Halfway House, Gauteng

South Africa

Chemical Manufacturing

41.0

 

Algorax (Pty) Ltd

Subsidiary

Estadeal, Eastern Cape

South Africa

Chemical Manufacturing

 

80

 



 

Competitors Report



CompanyName

Location

Employees

Ownership

Akzo Nobel N.V.

Amsterdam, Netherlands

55,590

Public

Altana AG

Wesel, Nordrhein-Westfalen, Germany

4,820

Public

BASF SE

Ludwigshafen Am Rhein, Germany

111,687

Public

ExxonMobil Chemical Company

Houston, Texas, United States

14,000

Private

H.C. Starck Gmbh

Munchen, Germany

2,816

Private

Johnson Matthey PLC

London, United Kingdom

10,058

Public

The Dow Chemical Company

Midland, Michigan, United States

53,444

Public

 

 

 

Executives Report

 

Board of Directors

 

Name

Title

Function

 

Wilhelm Bonse-Geuking

 

Supervisory Board of Directors

Chairman

 

Klaus Engel

 

Chairman of the Executive Board, Chief Executive Officer

Chairman

 

Biography:

Dr. Klaus Engel has been Chairman of the Executive Board and Chief Executive Officer of Evonik Industries AG since January 1, 2009. Before that, he served as Member of the Executive Board at the Company. Dr. Engel was also Chairman of the Board of Management of Evonik Degussa GmbH and acted as Chairman of the Management Board of Degussa AG between 2006 and 2008. From 2006 to 2007, he was active as Member of the Management Board at RAG Aktiengesellschaft. Previously, between 1999 and 2006, Dr. Engel was Member of the Management Board of Brenntag AG, including the position of Chairman of the Management Board at Brenntag AG from 2001 as well as Chief Executive Director of Brenntag Management GmbH from March 2004. He served as Managing Director of Creanova Spezialchemie GmbH at Marl Stinnes AG from 1998 until 1999. He is also active within the Boards of Vivawest GmbH and STEAG GmbH. Dr. Engel earned a degree in Chemistry from Ruhr-Universitaet Bochum in 1980 and gained a Doctorate from Ruhr-Universitaet Bochum in 1984.

 

Age: 57

 

Education:

Ruhr-Universitaet Bochum, DS
Ruhr-Universitaet Bochum (Chemistry)

 

Werner Mueller

 

Chairman of the Supervisory Board

Chairman

 

 

Biography:

Dr. Werner Mueller has been Chairman of the Supervisory Board of Evonik Industries AG since December 1, 2012. He is also Chairman of the Executive Board of RAG-Stiftung, and chairs the Supervisory Boards of RAG Aktiengesellschaft and RAG Deutsche Steinkohle AG. Dr. Mueller also acts as Member of the Board of Contilia GmbH and Stadler Rail AG.

 

Werner Bischoff

 

Vice Chairman-Supervisory Board

Vice-Chairman

 

Michael Vassiliadis

 

Deputy Chairman of the Supervisory Board

Vice-Chairman

 

Biography:

Mr. Michael Vassiliadis has served as Deputy Chairman of the Supervisory Board of Evonik Industries AG since September 26, 2012. He is Chairman fo the Mining, Chemical and Energy Industrial Union (IG BCE). Mr. Vassiliadis also serves on the Supervisory Boards of K + S AG, STEAG GmbH, BASF SE, Henkel-AG & Co. KGaA, and RAG-Stiftung.

 

Age: 49

 

Wolfgang Colberg

 

Member of the Executive Board, Chief Financial Officer

Director/Board Member

 

 

Biography:

Dr. Wolfgang Colberg has been Member of the Executive Board and Chief Financial Officer of Evonik Industries AG since April 1, 2009. Before joining the Company, he served as Member of the Board of Management (CFO) of BSH Bosch und Siemens Hausgeraete GmbH from 2001. Between 1996 and 2000, Dr. Colberg occupied the position of Senior Vice President Central Purchasing and Logistics at Robert Bosch GmbH. From 1994 to 1996, he acted as General Manager for Turkey and Central Asia at Robert Bosch Turkey. From 1993 to 1994 he was Section Head of Economic Planning and Controlling at Robert Bosch GmbH, from 1990 to 1993 Head of Business Administration and from 1986 to 1989 responsible for Corporate Strategy as well as Controlling and Merger & Acquisition (M&A) at the company. Currently, Dr. Colberg acts on the Supervisory Board of Steag GmbH, Pernod Ricard SA, and as Chairman of the Supervisory Board of Evonik Services GmbH, among others. Dr. Colberg studied Business Administration and Commercial Information Technology in Kiel, with periods of study in France and the United States between 1980 and 1985. He holds a degree in Business Administration and earned a Doctorate in Politics from Christian-Albrechts-Universitaet zu Kiel in 1993.

 

Age: 53

 

Education:

Christian-Albrechts-Universitaet zu Kiel, DS (Politics)
Christian-Albrechts-Universitaet zu Kiel (Business Administration)

 

Barbara Grunewald

 

Member of the board of directors

Director/Board Member

 

Thomas Haeberle

 

Member of the Executive Board

Director/Board Member

 

Biography:

Dr. Thomas Haeberle has been Member of the Executive Board of Evonik Industries AG since April 1, 2011. He studied process technology at Universitaet Erlangen- Nuremberg where he was awarded a doctorate in Engineering. Dr. Haeberle started his career at Roehm GmbH in Darmstadt, where he was responsible for the monomers business and PLEXIGLAS molding compounds. In 2003 he moved from Roehm GmbH to take up a post on the Board of Management of Infracor GmbH, becoming its Chairman from 2004 until 2006. In 2006 he joined Degussa AG, initially as Head of the Building Blocks Business Unit. In 2008 he became Head of the Industrial Chemicals Business Unit at Evonik Degussa GmbH, a position he held until he was appointed to the Board of Management of Evonik Degussa GmbH in 2009. He serves on Board of Evonik Services GmbH.

 

Age: 57

 

Education:

University of Erlangen-Nuremberg, PHD (Engineering)

 

Rainer Kumlehn

 

Supervisory Board of Directors

Director/Board Member

 

Michael Rüdiger

 

Member of the board of directors

Director/Board Member

 

Thomas Wessel

 

Member of the Executive Board, Director of Human Resources

Director/Board Member

 

Biography:

Mr. Thomas Wessel has been Member of the Executive Board and Director of Human Resources at Evonik Industries AG since September 1, 2011. Having qualified as an industrial clerk at Bergbau AG, he trained as a personnel officer and subsequently studied human resources management. Mr. Wessel began his career in the human resources department at Bergbau AG, Lippe, and subsequently moved to the Personnel Policy Issues Department at RAG Aktiengesellschaft, which he headed from 1997. From 2001 until 2002 his roles also included heading the Human Resources Division and the Human Resources Policy Department at RAG Aktiengesellschaft. From 2002 until 2006 he headed the Human Resources Division at RAG Aktiengesellschaft. During this time Mr. Wessel was also a member of the Board of Management of RAG Beteiligungs- GmbH. In 2006 he was appointed Chairman of the Board of Management of RAG BILDUNG GmbH. In 2009 he joined Evonik Degussa AG as Chief Human Resources Officer and a member of the Board of Management. He also serves as Chairman of the Board of Industriepark Wolfgang GmbH, Infracor GmbH and Member of the Board of Gesellschaft zur Sicherung von Bergmannswohnungen mbH and THS GmbH, among others.

 

Age: 50

 

Patrik Wohlhauser

 

Member of the Executive Board

Director/Board Member

 

 

Biography:

Mr. Patrik Wohlhauser has been Member of the Executive Board of Evonik Industries AG since April 1, 2011. He took a business administration degree at Universite de Fribourg followed by the Accelerated Management Development Programme at London Business School. At the start of his career Mr. Wohlhauser was employed in Operational Auditing at SANDOZ INTERNATIONAL AG. He was Operations Manager at MBT SCHWEIZ AG from 1993, and Director Sales at this company from 1995. In 1997 he was appointed CEO of MBT FRANCE. In 2002 he moved to Degussa AG, initially as head of the Construction Systems Europe Business Unit and from 2005 as head of the Exclusive Synthesis & Catalysts Business Unit. From 2007 he was a member of the Board of Management of Evonik Degussa GmbH, becoming Chairman in 2009.

 

Age: 49

 

Education:

Freiburg University (Business Administration)

 

Dahai Yu

 

Member of the Executive Board

Director/Board Member

 

 

Biography:

Dr. Dahai Yu has been Member of the Executive Board of Evonik Industries AG since April 1, 2011. He studied chemistry at the Universitaet Hamburg, where he obtained his doctorate in 1989. Following a research scholarship, he joined Degussa AG as a laboratory manager in Central Research in 1990. His long career at Degussa included posts as product manager, director of the Corporate Development and Strategy Planning department, head of controlling for the Fine & Industrial Chemicals Business Unit and head of the Agrochemicals & Intermediates Business Line. In 2006 Dr. Yu returned to Shanghai as President of Evonik’s Greater China Region and Chairman of Evonik Degussa (China) Co., Ltd.

 

Age: 52

 

Education:

University of Hamburg, PHD (Chemistry)

 

 

Executives

 

Name

Title

Function

 

Klaus Engel

 

Chairman of the Executive Board, Chief Executive Officer

Chief Executive Officer

 

Biography:

Dr. Klaus Engel has been Chairman of the Executive Board and Chief Executive Officer of Evonik Industries AG since January 1, 2009. Before that, he served as Member of the Executive Board at the Company. Dr. Engel was also Chairman of the Board of Management of Evonik Degussa GmbH and acted as Chairman of the Management Board of Degussa AG between 2006 and 2008. From 2006 to 2007, he was active as Member of the Management Board at RAG Aktiengesellschaft. Previously, between 1999 and 2006, Dr. Engel was Member of the Management Board of Brenntag AG, including the position of Chairman of the Management Board at Brenntag AG from 2001 as well as Chief Executive Director of Brenntag Management GmbH from March 2004. He served as Managing Director of Creanova Spezialchemie GmbH at Marl Stinnes AG from 1998 until 1999. He is also active within the Boards of Vivawest GmbH and STEAG GmbH. Dr. Engel earned a degree in Chemistry from Ruhr-Universitaet Bochum in 1980 and gained a Doctorate from Ruhr-Universitaet Bochum in 1984.

 

Age: 57

 

Education:

Ruhr-Universitaet Bochum, DS
Ruhr-Universitaet Bochum (Chemistry)

 

Gerard Berote

 

Managing Director Taiwan operations

Managing Director

 

Guenter Adam

 

Member of the Supervisory Board

Administration Executive

 

Biography:

Mr. Guenter Adam is Member of the Supervisory Board of Evonik Industries AG. He is Deputy Chairman of the Central Works Council, and Chairman of the works Council of the Hanau facilities.

 

Peter Bettermann

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Dr. Peter Bettermann is Member of the Supervisory Board of Evonik Industries AG. He is also a former Management Board Spokesman of Freudenberg Co KG. In addition, he serves as Chairman of the Supervisory Board of BATIG Gesellschaft fuer Beteiligungen GmbH, British American Tobacco (Germany) GmbH, as well as Member on the Supervisory Board of British American Tobacco (Industries) GmbH. He is also active within the Board of Wilh. Werhahn KG.

 

Age: 65

 

Karin Erhard

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Ms. Karin Erhard has been Member of the Supervisory Board of Evonik Industries AG since November 14, 2012, She is Head of the Department for Collective Bargaining Law and Pay-Scale Planning of the Mining, Chemical and Energy Industrial Union (IG BCE). Ms. Erhard also serves on the Supervisory Boards of INEOS Deutschland GmbH and INEOS Koeln GmbH.

 

Hans Michael Gaul

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Dr. Hans Michael Gaul is Member of the Supervisory Board of Evonik Industries AG. He also sits on the Supervisory Boards of BDO AG, HSBC Trinkaus & Burkhardt AG, and Siemens AG.

 

Age: 71

 

Stephan Gemkow

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Stephan Gemkow is Member of the Supervisory Board of Evonik Industries AG. Furthermore, he serves as Chairman of Celesio AG and TAKKT AG. He is also on the Boards of Amadeus IT Group S.A., Amadeus IT Holding S.A., and JetBlue Airways Corporation.

 

Age: 53

 

Ralf Giesen

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Ralf Giesen is Member of the Supervisory Board of Evonik Industries AG. Furthermore, he acts as Secretary of the Board of the Mining, Chemical and Energy Industrial Union. He is Member of the Supervisory Board of Altana AG.

 

Ralf Hermann

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Ralf Hermann is Member of the Supervisory Board of Evonik Industries AG. He is Chairman of the Central Works Council of Evonik Industries AG. He is also active within the RAG-Stiftung.

 

Wolfgang A. Herrmann

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Prof. Dr. Wolfgang A. Herrmann is Member of the Supervisory Board of Evonik Industries AG. In addition, he acts as President of Technische Universitaet Muenchen. He is also Member of the Supervisory Board of Bayerische Forschungsallianz GmbH.

 

Dieter Kleren

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Dieter Kleren has been Member of the Supervisory Board of Evonik Industries AG since August 1, 2011. He also serves as Chairman of the Works Council for the Wesseling facilities.

 

Steve Koltes

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Steve Koltes is Member of the Supervisory Board of Evonik Industries AG. Furthermore, he serves as Managing Director of CVC Capital Partners Luxembourg S.a.r.C. He is also active on the Boards of Flint Group Investments S.à r.l., Flint Group S.à r.l. and Flint Group Holdings S.a.r.l.

 

Education:

Middlebury College, BA

 

Siegfried Luther

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Dr. Siegfried Luther is Member of the Supervisory Board of Evonik Industries AG. He is former Chief Financial Officer of Bertelsmann AG. In addition, he is Member of the Supervisory Board of Schaeffler AG and Sparkasse Guetersloh. He is also Chairman of the Board of RTL S.A. He holds a Juris Doctor degree in Law from Westfaelische Wilhelms-Universitaet Muenster.

 

Age: 68

 

Education:

Westfaelische Wilhelms-Universitaet Muenster, JD (Law)

 

Juergen Noeding

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Juergen Noeding acts as Member of the Supervisory Board of Evonik Industries AG. Additionally, he serves as Chairman of the General Works Council at Evonik Services GmbH, where he also acts as Member of the Supervisory Board.

 

Norbert Pohlmann

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Norbert Pohlmann has been Member of the Supervisory Board of Evonik Industries AG since August 1, 2011. He also serves as Chairman of the Works Council for the Goldschmidtstrasse facilities and is active on the Board of BKK Novitas.

 

Wilfried Robers

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Dr. Wilfried Robers acts as Member of the Supervisory Board of Evonik Industries AG. He is Chairman of the Executive Staff Representation Committee at the Company. He is also active within the Pensionskasse Degussa VVaG.

 

Christian H. Strenger

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Christian H. Strenger is Member of the Supervisory Board of Evonik Industries AG. He is former Spokesman of the Supervisory Board of DWS Investment GmbH. He is Member of the Supervisory Board of DWS Investment GmbH, TUI AG and Fraport AG. He is also Chairman of the Board at The Germany Funds.

 

Ulrich Terbrack

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Mr. Ulrich Terbrack has been Member of the Supervisory Board of Evonik Industries AG since March 12, 2011. He also serves as Deputy Chairman of the Central Works Council of Evonik Industries AG.

 

Volker Trautz

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Dr. Volker Trautz is Member of the Supervisory Board of Evonik Industries AG. He is former Chairman of the Supervisory Board of LyondellBasell Industrie Holdings BV. He is Member of the Supervisory Board of Citigroup Global Markets Deutschland AG and is active on the Boards of CERONA Companhia de Energia Renovavel, OSF Merchant Banking and La Seda de Barcelona.

 

Christian Wildmoser

 

Member of the Supervisory Board

Administration Executive

 

 

Biography:

Dr. Christian Wildmoser is Member of the Supervisory Board of Evonik Industries AG. In addition, he acts as Managing Director of CVC Capital Partners Switzerland GmbH. He is also active within the Board at Flint Group Holdings S.a.r.l., Flint Group Investments S.a r.l. and Flint Group S.a r.l.

 

Wolfgang Colberg

 

Member of the Executive Board, Chief Financial Officer

Finance Executive

 

 

Biography:

Dr. Wolfgang Colberg has been Member of the Executive Board and Chief Financial Officer of Evonik Industries AG since April 1, 2009. Before joining the Company, he served as Member of the Board of Management (CFO) of BSH Bosch und Siemens Hausgeraete GmbH from 2001. Between 1996 and 2000, Dr. Colberg occupied the position of Senior Vice President Central Purchasing and Logistics at Robert Bosch GmbH. From 1994 to 1996, he acted as General Manager for Turkey and Central Asia at Robert Bosch Turkey. From 1993 to 1994 he was Section Head of Economic Planning and Controlling at Robert Bosch GmbH, from 1990 to 1993 Head of Business Administration and from 1986 to 1989 responsible for Corporate Strategy as well as Controlling and Merger & Acquisition (M&A) at the company. Currently, Dr. Colberg acts on the Supervisory Board of Steag GmbH, Pernod Ricard SA, and as Chairman of the Supervisory Board of Evonik Services GmbH, among others. Dr. Colberg studied Business Administration and Commercial Information Technology in Kiel, with periods of study in France and the United States between 1980 and 1985. He holds a degree in Business Administration and earned a Doctorate in Politics from Christian-Albrechts-Universitaet zu Kiel in 1993.

 

Age: 53

 

Education:

Christian-Albrechts-Universitaet zu Kiel, DS (Politics)
Christian-Albrechts-Universitaet zu Kiel (Business Administration)

 

Thomas Wessel

 

Member of the Executive Board, Director of Human Resources

Human Resources Executive

 

 

Biography:

Mr. Thomas Wessel has been Member of the Executive Board and Director of Human Resources at Evonik Industries AG since September 1, 2011. Having qualified as an industrial clerk at Bergbau AG, he trained as a personnel officer and subsequently studied human resources management. Mr. Wessel began his career in the human resources department at Bergbau AG, Lippe, and subsequently moved to the Personnel Policy Issues Department at RAG Aktiengesellschaft, which he headed from 1997. From 2001 until 2002 his roles also included heading the Human Resources Division and the Human Resources Policy Department at RAG Aktiengesellschaft. From 2002 until 2006 he headed the Human Resources Division at RAG Aktiengesellschaft. During this time Mr. Wessel was also a member of the Board of Management of RAG Beteiligungs- GmbH. In 2006 he was appointed Chairman of the Board of Management of RAG BILDUNG GmbH. In 2009 he joined Evonik Degussa AG as Chief Human Resources Officer and a member of the Board of Management. He also serves as Chairman of the Board of Industriepark Wolfgang GmbH, Infracor GmbH and Member of the Board of Gesellschaft zur Sicherung von Bergmannswohnungen mbH and THS GmbH, among others.

 

Age: 50

 

Alexandra Boy

 

Press Officer

Public Relations Executive

 

Barbara Muller

 

Head-Press & Press Officer

Public Relations Executive

 

Edda Schulze

 

Press Officer

Public Relations Executive

 

Ruben Thiel

 

Press Officer

Public Relations Executive

 

Oliver Luckenbach

 

Head of Investor Relations

Investor Relations Executive

 

Johannes Pfleger

 

Chemist

Research & Development Executive

 

Biography:

Johannes Pfleger first attended a middle school and then the Industrial School in Munich receiving a diploma in 1884. After completing his military service and a short stay in an infirmary following an accident he enrolled as a student in the Chemical-Technical Faculty at the Royal Technical University in Munich. Upon completion of his studies in 1891 (when a doctorate at a technical university was not yet possible) he joined Deutsche Gold- und Silber-Scheideanstalt (Degussa AG since 1980 and predecessor of the Chemicals Business Area of Evonik) in Frankfurt am Main as an industrial chemist. Just a year later as senior electronics chemist he took over the experimental facility for electrochemistry and electrometallurgy which was founded jointly by Degussa and Metallgesellschaft AG.

 

 

Significant Developments

 

 

 

 

Temasek Holdings To Buy Stake In Evonik Industries AG-Reuters

Mar 10, 2013


Reuters reported that Temasek Holdings will take a stake in Evonik Industries. Temasek will spend more than EUR600 million ($779 million) for 5% of the Essen-based chemicals company. German magazine Wirtschaftswoche reported on Saturday that Temasek and Evonik had agreed the sale. A spokesman for Temasek declined to confirm the deal.

Evonik Industries AG Cancells IPO-Reuters

Jun 19, 2012


Reuters reported that the owners of German chemical company Evonik Industries AG scrapped plans for what could have been Europe's biggest initial public offering (IPO) in more than a year and said it would only resume efforts for a listing if markets recover. RAG Foundation owns 75% of Evonik, which makes battery chemicals, animal feed additives, acrylic glass and absorbents for diapers. Private equity firm CVC holds the remaining 25%. RAG's board of trustees was set to decide against an IPO, after a meeting with bankers on Friday showed insufficient commitments to the IPO from investors. The banks promised too much. Expectations were created that were too high,' said one investment banker who was involved in the IPO preparations. Deutsche Bank and Goldman Sachs led preparations for the IPO, in which RAG and CVC planned to float about 30% of Evonik.

 

Annual Profit & Loss

 

 

 

 

31-Dec-2011

31-Dec-2010

31-Dec-2009

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate (Period Average)

0.71919

0.755078

0.719047

Consolidated

Yes

Yes

Yes

 

 

 

 

Total income

20,217.2

17,614.1

18,185.2

Net sales

20,217.2

17,614.1

18,185.2

Other operating income

1,409.9

1,278.0

1,208.5

Cost of sales

14,248.0

12,502.0

13,715.4

Gross profit

5,969.2

5,112.1

4,469.8

Advertising, distribution, and commercial expenses

1,726.9

1,554.8

1,451.9

General expenses

921.9

834.4

887.3

Other operating costs

2,253.9

2,239.5

2,214.0

Net operating income

2,476.4

1,761.4

1,125.1

Other income

36.2

18.5

41.7

Interest payable on loans

599.3

597.3

726.0

Total expenses

439.4

479.4

560.5

Profit before tax

2,037.0

1,282.0

564.6

Provisions

6,942.5

8,216.4

9,397.2

Total taxation

627.1

231.8

130.7

Net profit

1,409.9

1,050.2

433.9

 

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

31-Dec-2011

31-Dec-2010

31-Dec-2009

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.770327

0.745406

0.696986

Consolidated

Yes

Yes

Yes

 

 

 

 

Issued capital

604.9

625.2

668.6

Capital reserves

1,512.3

1,562.9

1,671.5

Profits for the year

5,929.9

5,296.4

5,057.5

Total stockholders equity

7,885.0

8,007.7

7,480.8

Minority interests

120.7

795.5

697.3

Deferred taxation

68.8

60.4

109.0

Other provisions

2,771.6

3,190.2

2,978.5

Provision for pensions

3,641.3

4,398.9

5,708.9

Provisions and allowances

6,481.7

8,323.0

9,694.6

Other debentures

1,119.0

1,179.2

2,736.1

Mortgages and loans

2,414.6

2,723.3

2,926.9

Advance payments

-

-

4.3

Taxes and social security

176.5

189.2

268.3

Total long-term liabilities

3,710.1

4,091.7

5,935.6

Trade creditors

1,409.8

1,459.6

1,958.4

Advances received

14.3

47.0

152.1

Other loans

515.4

407.8

622.7

Taxation and social security

858.1

4,707.5

693.0

Total current liabilities

2,797.5

6,621.9

3,426.2

Regularisation account

497.2

515.2

589.7

Total liabilities (including net worth)

21,995.9

27,559.5

27,126.8

Patents

562.1

684.2

873.8

Goodwill

3,562.1

3,842.2

4,568.2

Other intangibles

84.4

150.3

225.3

Intangibles

4,247.5

4,676.6

5,667.3

Land and buildings

3,675.1

3,852.9

4,407.6

Machinery and tools

2,965.0

3,186.2

4,185.2

Fixtures and equipment

3,675.1

3,852.9

4,407.6

Fixed assets under construction

791.9

770.0

1,542.4

Total tangible fixed assets

7,660.4

8,026.5

10,423.5

Participating interest

75.3

25.5

47.3

Deposits

122.0

116.7

229.6

Total financial assets

1,569.5

896.2

1,175.1

Total non-current assets

13,477.4

13,599.3

17,265.8

Raw materials

573.8

649.3

819.2

Work in progress

159.7

140.9

210.9

Finished goods

1,402.0

1,336.2

1,251.1

Net stocks and work in progress

2,135.5

2,126.4

2,281.3

Trade debtors

2,221.1

2,449.7

3,081.8

Other receivables

777.6

6,639.3

2,523.7

Total receivables

2,998.7

9,089.0

5,605.6

Cash and liquid assets

2,088.7

1,479.7

1,269.8

Short-term investments

582.9

520.5

33.0

Shares in associated companies

1,372.1

754.0

898.2

Recoverable taxation

619.2

694.9

562.4

Total current assets

7,805.8

13,215.6

9,189.6

Prepaid expenses and deferred costs

93.5

49.6

109.0

Total assets

21,995.9

27,559.5

27,126.8

 

 

 

Annual Ratios

Financials in: USD (mil)

 

 

 

31-Dec-2011

31-Dec-2010

31-Dec-2009

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.770327

0.745406

0.696986

Consolidated

Yes

Yes

Yes

 

 

 

 

Current ratio

27.90

19.96

26.82

Acid test ratio

20.27

16.75

20.16

Total liabilities to net worth

0.08%

0.13%

0.13%

Net worth to total assets

0.04%

0.03%

0.03%

Current liabilities to net worth

0.04%

0.08%

0.05%

Current liabilities to stock

0.13%

0.31%

0.15%

Fixed assets to net worth

0.17%

0.17%

0.23%

Collection period

431.00

500.00

599.00

Stock turnover rate

1.13

1.19

1.22

Profit margin

0.01%

0.01%

0.00%

Return on assets

0.01%

0.01%

0.00%

Shareholders' return

0.02%

0.01%

0.01%

Sales per employee

43.17

38.86

32.88

Profit per employee

3.01

2.32

0.78

Net worth

7,885.0

8,007.7

7,480.8

Number of employees

33,931

34,223

39,768

 

 

 

ANNUAL INCOME STATEMENT

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 Financial Glossary

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Reclassified Normal
31-Dec-2011

Restated Normal
31-Dec-2010

Restated Normal
31-Dec-2009

Filed Currency

EUR

EUR

EUR

EUR

EUR

Exchange Rate (Period Average)

0.778237

0.71919

0.755078

0.719047

0.683679

Auditor

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Net Sales

17,512.7

21,617.4

18,881.5

15,809.8

24,725.0

Revenue

17,512.7

21,617.4

18,881.5

15,809.8

24,725.0

    Interest Income, Non-Bank

-

19.5

14.6

-

-

Other Revenue, Total

-

19.5

14.6

-

-

Total Revenue

17,512.7

21,636.9

18,896.1

15,809.8

24,725.0

 

 

 

 

 

 

    Cost of Revenue

12,464.1

14,248.0

12,502.0

10,750.3

18,113.8

Cost of Revenue, Total

12,464.1

14,248.0

12,502.0

10,750.3

18,113.8

Gross Profit

5,048.6

7,369.4

6,379.5

5,059.5

6,611.3

 

 

 

 

 

 

    Selling/General/Administrative Expense

2,427.3

3,186.9

2,998.4

3,645.1

4,613.3

Total Selling/General/Administrative Expenses

2,427.3

3,186.9

2,998.4

3,645.1

4,613.3

Research & Development

505.0

507.5

447.6

414.4

454.9

        Investment Income - Operating

-

837.1

921.8

-

-

    Interest/Investment Income - Operating

-

837.1

921.8

-

-

Interest Expense (Income) - Net Operating Total

-

837.1

921.8

-

-

    Restructuring Charge

-

11.1

41.1

82.1

92.1

    Impairment-Assets Held for Use

-

239.2

190.7

175.2

465.1

    Loss (Gain) on Sale of Assets - Operating

-

52.8

21.2

12.5

-172.6

    Other Unusual Expense (Income)

-

-

-

-

-29.3

Unusual Expense (Income)

-

303.1

253.0

269.8

355.4

    Other Operating Expense

1,657.6

-

-

-

-

    Other, Net

-1,953.1

-

-

-

-

Other Operating Expenses, Total

-295.5

-

-

-

-

Total Operating Expense

15,100.8

19,082.6

17,122.7

15,079.7

23,537.4

 

 

 

 

 

 

Operating Income

2,411.9

2,554.3

1,773.3

730.1

1,187.7

 

 

 

 

 

 

        Interest Expense - Non-Operating

-503.7

-344.8

-323.1

-596.6

-886.4

    Interest Expense, Net Non-Operating

-503.7

-344.8

-323.1

-596.6

-886.4

        Interest Income - Non-Operating

45.0

69.5

30.5

44.5

111.2

        Investment Income - Non-Operating

111.8

111.2

71.5

79.3

93.6

    Interest/Investment Income - Non-Operating

156.8

180.8

102.0

123.8

204.8

Interest Income (Expense) - Net Non-Operating Total

-346.9

-164.1

-221.2

-472.8

-681.6

    Other Non-Operating Income (Expense)

6.4

-244.7

-260.9

5.6

23.4

Other, Net

6.4

-244.7

-260.9

5.6

23.4

Income Before Tax

2,071.3

2,145.5

1,291.3

262.8

529.5

 

 

 

 

 

 

Total Income Tax

591.1

627.1

231.8

75.1

187.2

Income After Tax

1,480.3

1,518.4

1,059.5

187.7

342.3

 

 

 

 

 

 

    Minority Interest

-3.9

-4.2

-78.1

-100.1

-102.4

Net Income Before Extraord Items

1,476.4

1,514.2

981.4

87.6

239.9

    Discontinued Operations

19.3

-108.5

-9.3

246.2

171.1

Total Extraord Items

19.3

-108.5

-9.3

246.2

171.1

Net Income

1,495.7

1,405.7

972.1

333.8

411.0

 

 

 

 

 

 

Income Available to Common Excl Extraord Items

1,476.4

1,514.2

981.4

87.6

239.9

 

 

 

 

 

 

Income Available to Common Incl Extraord Items

1,495.7

1,405.7

972.1

333.8

411.0

 

 

 

 

 

 

Basic/Primary Weighted Average Shares

466.0

466.0

464.6

466.0

466.0

Basic EPS Excl Extraord Items

3.17

3.25

2.11

0.19

0.51

Basic/Primary EPS Incl Extraord Items

3.21

3.02

2.09

0.72

0.88

Dilution Adjustment

-

-

-

0.0

-

Diluted Net Income

1,495.7

1,405.7

972.1

333.8

411.0

Diluted Weighted Average Shares

466.0

466.0

464.6

466.0

466.0

Diluted EPS Excl Extraord Items

3.17

3.25

2.11

0.19

0.51

Diluted EPS Incl Extraord Items

3.21

3.02

2.09

0.72

0.88

Dividends per Share - Common Stock Primary Issue

0.00

1.27

1.14

0.96

0.00

Gross Dividends - Common Stock

0.0

590.9

529.7

-

0.0

Interest Expense, Supplemental

503.7

344.8

323.1

596.6

886.4

Depreciation, Supplemental

1,028.0

707.7

819.8

860.9

947.8

Total Special Items

-

329.5

238.4

269.8

355.4

Normalized Income Before Tax

2,071.3

2,475.0

1,529.6

532.6

884.9

 

 

 

 

 

 

Effect of Special Items on Income Taxes

-

96.3

42.8

77.1

125.7

Inc Tax Ex Impact of Sp Items

591.1

723.4

274.6

152.2

312.9

Normalized Income After Tax

1,480.3

1,751.6

1,255.1

380.5

572.0

 

 

 

 

 

 

Normalized Inc. Avail to Com.

1,476.4

1,747.4

1,177.0

280.3

469.6

 

 

 

 

 

 

Basic Normalized EPS

3.17

3.75

2.53

0.60

1.01

Diluted Normalized EPS

3.17

3.75

2.53

0.60

1.01

Amort of Intangibles, Supplemental

-

130.7

151.0

187.7

220.9

Rental Expenses

-

129.3

123.2

-

-

Research & Development Exp, Supplemental

505.0

507.5

447.6

414.4

454.9

Normalized EBIT

2,411.9

3,720.9

2,933.5

999.9

1,543.1

Normalized EBITDA

3,439.8

4,559.3

3,904.2

2,048.5

2,711.8

    Current Tax - Domestic

-

545.1

529.7

-

188.7

Current Tax - Total

-

545.1

529.7

-

188.7

    Deferred Tax - Domestic

-

82.0

-298.0

-

-1.5

Deferred Tax - Total

-

82.0

-298.0

-

-1.5

Income Tax - Total

-

627.1

231.8

-

187.2

Interest Cost - Domestic

-

504.7

495.3

521.5

555.8

Service Cost - Domestic

-

148.8

123.2

118.2

146.3

Expected Return on Assets - Domestic

-

-250.3

-221.2

-218.3

-241.3

Curtailments & Settlements - Domestic

-

8.3

11.9

0.0

-1.5

Other Pension, Net - Domestic

-

29.2

111.2

30.6

49.7

Domestic Pension Plan Expense

-

440.8

520.5

452.0

509.0

Defined Contribution Expense - Domestic

-

-

-

-

231.1

Defined Contribution Expense - Foreign

-

-

-

-

13.2

Total Pension Expense

-

440.8

520.5

452.0

753.3

Discount Rate - Domestic

-

4.75%

5.00%

5.50%

6.00%

Discount Rate - Foreign

-

4.76%

5.03%

5.54%

6.02%

Expected Rate of Return - Domestic

-

4.80%

4.93%

5.00%

5.00%

Expected Rate of Return - Foreign

-

5.05%

5.35%

5.35%

5.41%

Compensation Rate - Domestic

-

2.50%

2.54%

2.53%

2.53%

Compensation Rate - Foreign

-

2.60%

2.62%

2.63%

2.68%

Pension Payment Rate - Domestic

-

2.00%

2.00%

2.00%

2.00%

Pension Payment Rate - Foreign

-

2.02%

2.06%

2.07%

2.02%

Total Plan Interest Cost

-

504.7

495.3

521.5

555.8

Total Plan Service Cost

-

148.8

123.2

118.2

146.3

Total Plan Expected Return

-

-250.3

-221.2

-218.3

-241.3

Total Plan Other Expense

-

29.2

111.2

30.6

49.7

 




 

Annual Balance Sheet

Financials in: USD (mil)

 

  Financial Glossary

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

UpdateType/Date

Updated Normal
31-Dec-2012

Reclassified Normal
31-Dec-2012

Updated Normal
31-Dec-2010

Updated Normal
31-Dec-2009

Restated Normal
31-Dec-2009

Filed Currency

EUR

EUR

EUR

EUR

EUR

Exchange Rate

0.7566

0.770327

0.745406

0.696986

0.719399

Auditor

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Cash & Equivalents

979.4

1,829.1

1,479.7

1,269.8

745.1

    Short Term Investments

1,435.4

893.1

649.3

430.4

458.7

Cash and Short Term Investments

2,414.8

2,722.2

2,129.0

1,700.2

1,203.8

        Accounts Receivable - Trade, Gross

-

-

2,459.1

-

-

        Provision for Doubtful Accounts

-

-

-9.4

-

-

    Trade Accounts Receivable - Net

2,229.7

2,221.1

2,449.7

3,081.8

3,575.2

    Other Receivables

589.5

542.6

320.6

604.0

735.3

Total Receivables, Net

2,819.2

2,763.8

2,770.3

3,685.9

4,310.5

    Inventories - Finished Goods

-

-

1,336.2

1,251.1

1,915.5

    Inventories - Work In Progress

-

-

140.9

210.9

208.5

    Inventories - Raw Materials

-

-

649.3

819.2

928.6

Total Inventory

2,270.7

2,135.5

2,126.4

2,281.3

3,052.5

Prepaid Expenses

-

-

87.2

134.9

-

    Discontinued Operations - Current Asset

44.9

61.0

6,039.7

0.0

286.4

Other Current Assets, Total

44.9

61.0

6,039.7

0.0

286.4

Total Current Assets

7,549.6

7,682.5

13,152.6

7,802.2

8,853.2

 

 

 

 

 

 

        Buildings

-

-

3,910.6

4,817.9

4,585.8

        Machinery/Equipment

-

-

15,630.4

20,428.0

18,814.3

        Construction in Progress

-

-

787.5

1,572.5

1,695.9

    Property/Plant/Equipment - Gross

-

-

20,328.5

26,818.3

25,096.0

    Accumulated Depreciation

-

-

-14,351.9

-18,624.5

-17,178.2

Property/Plant/Equipment - Net

5,943.7

5,654.7

5,976.6

8,193.9

7,917.7

Goodwill, Net

-

-

3,842.2

4,568.2

4,448.2

    Intangibles - Gross

-

-

3,195.6

3,513.7

-

    Accumulated Intangible Amortization

-

-

-2,361.1

-2,414.7

-

Intangibles, Net

4,216.2

4,247.5

834.4

1,099.0

1,231.6

    LT Investment - Affiliate Companies

1,496.2

1,372.1

754.0

898.2

839.6

    LT Investments - Other

2,309.0

2,336.7

2,194.8

3,865.2

4,013.1

Long Term Investments

3,805.2

3,708.8

2,948.7

4,763.4

4,852.7

Note Receivable - Long Term

74.0

83.1

110.0

137.7

151.5

    Deferred Income Tax - Long Term Asset

434.8

619.2

694.9

562.4

506.0

Other Long Term Assets, Total

434.8

619.2

694.9

562.4

506.0

Total Assets

22,023.5

21,995.9

27,559.5

27,126.8

27,960.9

 

 

 

 

 

 

Accounts Payable

1,448.6

1,409.8

1,459.6

1,958.4

2,033.6

Accrued Expenses

-

-

59.0

74.6

-

Notes Payable/Short Term Debt

0.0

0.0

104.6

0.0

0.0

Current Portion - Long Term Debt/Capital Leases

1,960.1

521.9

307.2

652.8

1,401.2

    Customer Advances

-

-

47.0

152.1

-

    Income Taxes Payable

294.7

456.9

462.8

360.1

273.8

    Other Payables

359.5

368.7

-

-

-

    Discontinued Operations - Current Liability

17.2

114.2

3,980.4

0.0

119.5

    Other Current Liabilities

1,493.5

1,524.0

2,228.3

1,825.0

2,229.6

Other Current liabilities, Total

2,164.9

2,463.9

6,718.5

2,337.2

2,623.0

Total Current Liabilities

5,573.6

4,395.5

8,649.0

5,023.1

6,057.8

 

 

 

 

 

 

    Long Term Debt

1,935.0

3,563.4

3,838.2

5,663.0

5,952.2

    Capital Lease Obligations

-

-

8.0

133.4

155.7

Total Long Term Debt

1,935.0

3,563.4

3,846.2

5,796.4

6,107.9

Total Debt

3,895.1

4,085.3

4,258.1

6,449.2

7,509.1

 

 

 

 

 

 

    Deferred Income Tax - LT Liability

611.9

624.4

673.5

898.2

955.0

Deferred Income Tax

611.9

624.4

673.5

898.2

955.0

Minority Interest

146.7

120.7

795.5

697.3

668.6

    Reserves

1,175.0

1,316.3

1,282.5

1,565.3

1,479.0

    Pension Benefits - Underfunded

3,141.7

3,641.3

4,398.9

5,708.9

5,494.9

    Other Long Term Liabilities

560.4

569.9

701.6

654.2

700.6

Other Liabilities, Total

4,877.1

5,527.5

6,383.1

7,928.4

7,674.5

Total Liabilities

13,144.3

14,231.6

20,347.3

20,343.3

21,463.8

 

 

 

 

 

 

    Common Stock

615.9

604.9

625.2

668.6

647.8

Common Stock

615.9

604.9

625.2

668.6

647.8

Retained Earnings (Accumulated Deficit)

8,263.3

7,159.3

6,587.0

6,114.9

5,849.3

Total Equity

8,879.2

7,764.2

7,212.2

6,783.5

6,497.1

 

 

 

 

 

 

Total Liabilities & Shareholders’ Equity

22,023.5

21,995.9

27,559.5

27,126.8

27,960.9

 

 

 

 

 

 

    Shares Outstanding - Common Stock Primary Issue

466.0

466.0

466.0

466.0

466.0

Total Common Shares Outstanding

466.0

466.0

466.0

466.0

466.0

Treasury Shares - Common Stock Primary Issue

0.0

0.0

-

-

-

Employees

-

-

34,407

38,681

40,767

Accumulated Intangible Amort, Suppl.

-

-

2,361.1

2,414.7

2,143.5

Deferred Revenue - Current

-

-

47.0

152.1

-

Deferred Revenue - Long Term

-

-

0.0

4.3

-

Total Capital Leases, Supplemental

-

-

12.1

163.6

183.5

Capital Lease Payments Due in Year 1

-

-

2.7

30.1

27.8

Capital Lease Payments Due in Year 2

-

-

2.0

18.7

22.2

Capital Lease Payments Due in Year 3

-

-

2.0

18.7

22.2

Capital Lease Payments Due in Year 4

-

-

2.0

18.7

22.2

Capital Lease Payments Due in Year 5

-

-

2.0

18.7

22.2

Capital Lease Payments Due in 2-3 Years

-

-

4.0

37.3

44.5

Capital Lease Payments Due in 4-5 Years

-

-

4.0

37.3

44.5

Cap. Lease Pymts. Due in Year 6 & Beyond

-

-

1.3

58.8

66.7

Total Operating Leases, Supplemental

-

-

478.9

520.8

417.0

Operating Lease Payments Due in Year 1

-

-

83.2

91.8

61.2

Operating Lease Payments Due in Year 2

-

-

53.7

58.1

47.6

Operating Lease Payments Due in Year 3

-

-

53.7

58.1

47.6

Operating Lease Payments Due in Year 4

-

-

53.7

58.1

47.6

Operating Lease Payments Due in Year 5

-

-

53.7

58.1

47.6

Operating Lease Pymts. Due in 2-3 Years

-

-

107.3

116.2

95.2

Operating Lease Pymts. Due in 4-5 Years

-

-

107.3

116.2

95.2

Oper. Lse. Pymts. Due in Year 6 & Beyond

-

-

181.1

196.6

165.4

Pension Obligation - Domestic

-

-

9,361.3

4,678.7

4,102.0

Plan Assets - Domestic

-

-

4,763.8

4,535.2

4,045.0

Funded Status - Domestic

-

-

-4,597.5

-143.5

-57.0

Unfunded Plan Obligations

-

-

662.7

5,981.5

5,371.2

Total Funded Status

-

-

-5,260.2

-6,124.9

-5,428.1

Discount Rate - Domestic

-

-

5.00%

5.50%

6.00%

Discount Rate - Foreign

-

-

5.03%

5.54%

6.02%

Expected Rate of Return - Domestic

-

-

4.93%

5.00%

5.00%

Expected Rate of Return - Foreign

-

-

5.35%

5.35%

5.41%

Compensation Rate - Domestic

-

-

2.54%

2.53%

2.50%

Compensation Rate - Foreign

-

-

2.62%

2.63%

2.68%

Pension Payment Rate - Domestic

-

-

2.00%

2.00%

2.00%

Pension Payment Rate - Foreign

-

-

2.06%

2.07%

2.02%

Equity % - Domestic

-

-

9.90%

-

-

Debt Securities % - Domestic

-

-

79.70%

-

-

Real Estate % - Domestic

-

-

0.50%

-

-

Other Investments % - Domestic

-

-

9.90%

-

-

Total Plan Obligations

-

-

10,024.1

10,660.2

9,473.2

Total Plan Assets

-

-

4,763.8

4,535.2

4,045.0

 




 

Annual Cash Flows

Financials in: USD (mil)

 

  Financial Glossary

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Restated Normal
31-Dec-2012

Updated Normal
31-Dec-2010

Reclassified Normal
31-Dec-2010

Reclassified Normal
31-Dec-2009

Filed Currency

EUR

EUR

EUR

EUR

EUR

Exchange Rate (Period Average)

0.778237

0.71919

0.755078

0.719047

0.683679

Auditor

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

Net Income/Starting Line

2,411.9

2,554.3

1,773.3

730.1

1,187.7

    Depreciation

1,028.0

1,091.5

1,058.2

1,140.4

1,636.7

Depreciation/Depletion

1,028.0

1,091.5

1,058.2

1,140.4

1,636.7

    Discontinued Operations

0.0

-175.2

667.5

977.7

10.2

    Unusual Items

-5.1

7.0

-27.8

-20.9

-266.2

    Other Non-Cash Items

-452.3

-383.8

86.1

-331.0

-226.7

Non-Cash Items

-457.4

-552.0

725.8

625.8

-482.7

    Accounts Receivable

-41.1

-168.2

-327.1

93.2

-318.9

    Inventories

-163.2

-354.6

-237.1

616.1

-634.8

    Accounts Payable

-38.5

105.7

317.8

19.5

275.0

    Other Assets & Liabilities, Net

-231.3

-150.2

-99.3

91.8

-416.9

    Other Operating Cash Flow

-683.6

-706.4

-463.5

-407.5

-678.7

Changes in Working Capital

-1,157.7

-1,273.7

-809.2

413.0

-1,774.2

Cash from Operating Activities

1,824.6

1,820.1

2,748.1

2,909.4

567.5

 

 

 

 

 

 

    Purchase of Fixed Assets

-1,311.9

-1,230.6

-1,018.4

-1,125.1

-1,704.0

Capital Expenditures

-1,311.9

-1,230.6

-1,018.4

-1,125.1

-1,704.0

    Acquisition of Business

-56.5

-186.3

-72.8

-34.8

-122.9

    Sale of Business

-

1,419.7

83.4

175.2

482.7

    Sale of Fixed Assets

105.4

86.2

70.2

97.4

191.6

    Other Investing Cash Flow

-819.8

-920.5

-746.9

8.3

340.8

Other Investing Cash Flow Items, Total

-771.0

399.1

-666.2

246.2

892.2

Cash from Investing Activities

-2,082.9

-831.5

-1,684.6

-878.9

-811.8

 

 

 

 

 

 

    Other Financing Cash Flow

-14.1

-23.6

-31.8

-84.8

-51.2

Financing Cash Flow Items

-14.1

-23.6

-31.8

-84.8

-51.2

    Cash Dividends Paid - Common

-546.1

-556.2

-423.8

-389.4

-504.6

Total Cash Dividends Paid

-546.1

-556.2

-423.8

-389.4

-504.6

    Common Stock, Net

39.8

25.0

34.4

11.1

27.8

Issuance (Retirement) of Stock, Net

39.8

25.0

34.4

11.1

27.8

    Total Debt Issued

268.6

367.1

470.1

1,705.0

1,437.8

    Total Debt Reduction

-349.5

-696.6

-548.3

-2,789.8

-389.1

Issuance (Retirement) of Debt, Net

-81.0

-329.5

-78.1

-1,084.8

1,048.7

Cash from Financing Activities

-601.4

-884.3

-499.3

-1,547.9

520.7

 

 

 

 

 

 

Foreign Exchange Effects

-1.3

-20.9

53.0

-5.6

5.9

Net Change in Cash

-860.9

83.4

617.2

477.0

282.3

 

 

 

 

 

 

Net Cash - Beginning Balance

1,813.1

1,878.5

1,172.1

753.8

510.5

Net Cash - Ending Balance

952.2

1,961.9

1,789.2

1,230.8

792.8

Cash Interest Paid

208.2

269.7

263.5

-

326.2

Cash Taxes Paid

597.5

561.7

317.8

-

447.6

 

 

Annual Income Statement

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Reclassified Normal
31-Dec-2011

Restated Normal
31-Dec-2010

Restated Normal
31-Dec-2009

Filed Currency

EUR

EUR

EUR

EUR

EUR

Exchange Rate (Period Average)

0.778237

0.71919

0.755078

0.719047

0.683679

Auditor

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers LLP

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Revenues

17,512.7

20,217.2

17,614.1

14,627.7

23,217.0

    Other Operating Income

-

1,400.2

1,267.4

1,182.1

1,508.0

    Income from the Disposals of Assets

-

19.5

14.6

-

-

Total Revenue

17,512.7

21,636.9

18,896.1

15,809.8

24,725.0

 

 

 

 

 

 

    As Reported Other Operating Expense

1,657.6

-

-

-

-

    Income from the Disposals of Assets

-

-

-

-11.1

-285.2

    Research & Development

505.0

507.5

447.6

414.4

454.9

    Selling Expenses

1,595.9

1,726.9

1,586.6

1,408.8

1,774.2

    General Administrative Expenses

831.4

921.9

802.6

721.8

1,082.4

    Cost of Materials

12,464.1

14,248.0

12,502.0

10,750.3

18,113.8

    Other Operating Income

-1,953.1

-

-

-

-

    Reversal of Impairment

-

-

-

-

-29.3

    Translation Result

-

324.0

324.5

-

-

    Investment Result

-

513.1

597.3

-

-

    Impairment Losses Pursuant to IAS 36

-

203.0

169.5

94.6

406.6

    Impairment Losses Pursuant to IAS 39

-

23.6

21.2

27.8

46.8

    Impairment losses Pursuant to IFRS 5

-

12.5

0.0

52.8

11.7

    Expenses for Restructuring

-

11.1

41.1

82.1

92.1

    Loss on Disposal of Assets

-

52.8

21.2

23.6

112.6

    Other Operating Expenses

-

538.1

609.2

1,514.5

1,756.7

Total Operating Expense

15,100.8

19,082.6

17,122.7

15,079.7

23,537.4

 

 

 

 

 

 

    Interest Income

45.0

69.5

30.5

44.5

111.2

    Interest Expense

-503.7

-344.8

-323.1

-596.6

-886.4

    Investments Recognized at Equity

111.8

111.2

71.5

79.3

93.6

    Interest Expense/Pensions

-

-254.5

-274.1

-

-

    Other Financial Result

6.4

9.7

13.2

5.6

23.4

Net Income Before Taxes

2,071.3

2,145.5

1,291.3

262.8

529.5

 

 

 

 

 

 

Provision for Income Taxes

591.1

627.1

231.8

75.1

187.2

Net Income After Taxes

1,480.3

1,518.4

1,059.5

187.7

342.3

 

 

 

 

 

 

    Minority Interest

-3.9

-4.2

-78.1

-100.1

-102.4

Net Income Before Extra. Items

1,476.4

1,514.2

981.4

87.6

239.9

    Discontinued Operations

19.3

-108.5

-9.3

246.2

171.1

Net Income

1,495.7

1,405.7

972.1

333.8

411.0

 

 

 

 

 

 

Income Available to Com Excl ExtraOrd

1,476.4

1,514.2

981.4

87.6

239.9

 

 

 

 

 

 

Income Available to Com Incl ExtraOrd

1,495.7

1,405.7

972.1

333.8

411.0

 

 

 

 

 

 

Basic Weighted Average Shares

466.0

466.0

464.6

466.0

466.0

Basic EPS Excluding ExtraOrdinary Items

3.17

3.25

2.11

0.19

0.51

Basic EPS Including ExtraOrdinary Items

3.21

3.02

2.09

0.72

0.88

Dilution Adjustment

-

-

-

0.0

-

Diluted Net Income

1,495.7

1,405.7

972.1

333.8

411.0

Diluted Weighted Average Shares

466.0

466.0

464.6

466.0

466.0

Diluted EPS Excluding ExtraOrd Items

3.17

3.25

2.11

0.19

0.51

Diluted EPS Including ExtraOrd Items

3.21

3.02

2.09

0.72

0.88

DPS-Common Stock

0.00

1.27

1.14

0.96

0.00

Gross Dividends - Common Stock

0.0

590.9

529.7

-

0.0

Normalized Income Before Taxes

2,071.3

2,475.0

1,529.6

532.6

884.9

 

 

 

 

 

 

Inc Tax Ex Impact of Sp Items

591.1

723.4

274.6

152.2

312.9

Normalized Income After Taxes

1,480.3

1,751.6

1,255.1

380.5

572.0

 

 

 

 

 

 

Normalized Inc. Avail to Com.

1,476.4

1,747.4

1,177.0

280.3

469.6

 

 

 

 

 

 

Basic Normalized EPS

3.17

3.75

2.53

0.60

1.01

Diluted Normalized EPS

3.17

3.75

2.53

0.60

1.01

Depreciation of Tangibles

1,028.0

707.7

819.8

860.9

947.8

Amortization of Intangibles

-

130.7

151.0

187.7

220.9

Interest Expense

503.7

-

-

-

-

Interest Expense

-

344.8

323.1

596.6

886.4

Rental Expenses

-

129.3

123.2

-

-

Research & Development

505.0

507.5

447.6

414.4

454.9

    Current Tax

-

545.1

529.7

-

188.7

Current Tax - Total

-

545.1

529.7

-

188.7

    Deferred Tax

-

82.0

-298.0

-

-1.5

Deferred Tax - Total

-

82.0

-298.0

-

-1.5

Income Tax - Total

-

627.1

231.8

-

187.2

Current Service Cost

-

148.8

123.2

118.2

146.3

Interest Cost

-

504.7

495.3

521.5

555.8

Expected Return on Plan Assets

-

-250.3

-221.2

-218.3

-241.3

Amortization

-

9.7

263.5

132.1

-121.4

Effect of Curtailments & Settlements

-

8.3

11.9

0.0

-1.5

Effect of Assets Ceiling

-

16.7

-152.3

-101.5

171.1

Reclassification Pursuant to IFRS 5

-

2.8

0.0

-

-

Domestic Pension Plan Expense

-

440.8

520.5

452.0

509.0

Defined Contribution Expenses - Germany

-

-

-

-

231.1

Defined Contribution Expenses - Foreign

-

-

-

-

13.2

Total Pension Expense

-

440.8

520.5

452.0

753.3

Discount Rate - Domestic

-

4.75%

5.00%

5.50%

6.00%

Discount Rate - Foreign

-

4.76%

5.03%

5.54%

6.02%

Compensation Rate - Domestic

-

2.50%

2.54%

2.53%

2.53%

Compensation Rate - Foreign

-

2.60%

2.62%

2.63%

2.68%

Pension Increase - Domestic

-

2.00%

2.00%

2.00%

2.00%

Pension Increase - Foreign

-

2.02%

2.06%

2.07%

2.02%

Expected Return on Plan Assets-Domestic

-

4.80%

4.93%

5.00%

5.00%

Expected Return on Plan Assets - Foreign

-

5.05%

5.35%

5.35%

5.41%

 




 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

UpdateType/Date

Updated Normal
31-Dec-2012

Reclassified Normal
31-Dec-2012

Updated Normal
31-Dec-2010

Updated Normal
31-Dec-2009

Restated Normal
31-Dec-2009

Filed Currency

EUR

EUR

EUR

EUR

EUR

Exchange Rate

0.7566

0.770327

0.745406

0.696986

0.719399

Auditor

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers LLP

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

    Raw Materials

-

-

649.3

819.2

928.6

    Work in Progress

-

-

140.9

210.9

208.5

    Finished Goods

-

-

1,336.2

1,251.1

1,915.5

    Total Inventory

2,270.7

2,135.5

-

-

-

    Current Income Tax

104.4

77.9

63.1

228.1

180.7

    Reported Net Trade/Accounts Receivable

2,229.7

2,221.1

-

-

-

    Trade Receivables

-

-

-

3,081.8

3,575.2

    Trade Receivables Net

-

-

2,459.1

-

-

    Provisions for Doubtfull Accounts

-

-

-9.4

-

-

    Other Receivables

485.1

464.7

257.6

375.9

554.6

    Prepayments

-

-

56.3

61.7

-

    Defferals/Accruals

-

-

30.9

73.2

-

    Financial Current Assets

1,435.4

893.1

649.3

430.4

458.7

    Liquid Capital

979.4

1,829.1

1,479.7

1,269.8

745.1

    Assets Held for Sale

44.9

61.0

6,039.7

0.0

286.4

Total Current Assets

7,549.6

7,682.5

13,152.6

7,802.2

8,853.2

 

 

 

 

 

 

    Intangibles Gross

-

-

3,195.6

3,513.7

-

    Accumulated Amortization

-

-

-2,361.1

-2,414.7

-

    Intangible Assets

4,216.2

4,247.5

-

-

1,231.6

    Goodwill, Net

-

-

3,842.2

4,568.2

4,448.2

    Land, Landrights & Buildings

-

-

3,910.6

4,817.9

4,585.8

    Plant & Machinery

-

-

14,288.8

18,859.8

17,332.5

    Other Plant, Office Furniture& Equipment

-

-

1,341.6

1,568.2

1,481.8

    Advance Payments & Constr. in Progress

-

-

787.5

1,572.5

1,695.9

    Depreciation

-

-

-14,351.9

-18,624.5

-17,178.2

    Investment Property

2,048.6

2,005.6

2,049.9

2,229.6

2,087.9

    Investments Recognized at Equity

1,496.2

1,372.1

754.0

898.2

839.6

    Financial Assets

260.4

331.0

144.9

1,635.6

1,925.2

    Deferred Tax

434.8

619.2

694.9

562.4

506.0

    Other Income Tax Assets

27.8

29.9

30.9

57.4

50.0

    Other Receivables

46.3

53.2

79.2

80.3

101.5

    Property/Plant/Equipment

5,943.7

5,654.7

-

-

-

Total Assets

22,023.5

21,995.9

27,559.5

27,126.8

27,960.9

 

 

 

 

 

 

    Other Provisions

1,493.5

1,524.0

1,968.1

1,522.3

1,768.1

    Income Tax Liabilities

294.7

456.9

462.8

360.1

273.8

    Current Portion of LT Debt

-

-

303.2

622.7

1,373.4

    Current Portion of LT Leasing

-

-

4.0

30.1

27.8

    Financial Liabilities

1,960.1

521.9

-

-

-

    ST Debt

-

-

104.6

-

-

    Trade Payables

1,448.6

1,409.8

1,459.6

1,958.4

2,033.6

    Prepayments

-

-

47.0

152.1

-

    Deffrerals/Accruals

-

-

59.0

74.6

-

    Other Liabilities

-

-

260.3

302.7

461.5

    Liab. Assoc. with Assets Held for Sale

17.2

114.2

3,980.4

0.0

119.5

    Other Payables

359.5

368.7

-

-

-

Total Current Liabilities

5,573.6

4,395.5

8,649.0

5,023.1

6,057.8

 

 

 

 

 

 

    Long-Term Debt

1,935.0

3,563.4

3,838.2

5,663.0

5,952.2

    Long-Term Financial Leasing

-

-

8.0

133.4

155.7

Total Long Term Debt

1,935.0

3,563.4

3,846.2

5,796.4

6,107.9

 

 

 

 

 

 

    Provisions for Pensions & Other Benefits

3,141.7

3,641.3

4,398.9

5,708.9

5,494.9

    Other Provisions

1,175.0

1,316.3

1,282.5

1,565.3

1,479.0

    Deferred Tax Liabilities

611.9

624.4

673.5

898.2

955.0

    Other Income Tax Liabilies

152.0

90.9

93.9

87.5

166.8

    Financial Liabilities

-

-

64.4

-

-

    Other Liabilitiess

408.4

479.0

543.3

566.7

533.8

    Minority Interest

146.7

120.7

795.5

697.3

668.6

Total Liabilities

13,144.3

14,231.6

20,347.3

20,343.3

21,463.8

 

 

 

 

 

 

    Capital Issued

615.9

604.9

625.2

668.6

647.8

    Reserves

8,263.3

7,159.3

-

-

-

    Capital Reserve

-

-

1,562.9

1,671.5

1,619.4

    Accumulated Income/Loss

-

-

5,296.4

5,057.5

4,951.4

    Accumulated Other Comprehensive Income

-

-

-272.3

-614.1

-721.4

Total Equity

8,879.2

7,764.2

7,212.2

6,783.5

6,497.1

 

 

 

 

 

 

Total Liabilities & Shareholders' Equity

22,023.5

21,995.9

27,559.5

27,126.8

27,960.9

 

 

 

 

 

 

    S/O-Common Stock

466.0

466.0

466.0

466.0

466.0

Total Common Shares Outstanding

466.0

466.0

466.0

466.0

466.0

T/S-Common Stock

0.0

0.0

-

-

-

Deferred Income - Current

-

-

47.0

152.1

-

Deferred Income - Long-Term

-

-

0.0

4.3

-

Accumulated Amortization of Intangibles

-

-

2,361.1

2,414.7

2,143.5

Employees

-

-

34,407

38,681

40,767

Capital Lease Maturing Within 1 Year

-

-

2.7

30.1

27.8

Capital Lease Maturing in 1 - 5 Years

-

-

8.0

74.6

89.0

Capital Lease Payment - Remaining Part

-

-

1.3

58.8

66.7

Total Capital Leases, Supplemental

-

-

12.1

163.6

183.5

Operating Lease Maturing Within 1 Year

-

-

83.2

91.8

61.2

Operating Lease Maturing in 1 - 5 Years

-

-

214.6

232.4

190.4

Operating Lease Payment - Remaining Part

-

-

181.1

196.6

165.4

Total Operating Leases, Supplemental

-

-

478.9

520.8

417.0

Unfunded Plan Obligations

-

-

662.7

5,981.5

5,371.2

Present Value of Defined Benefit Oblig.

-

-

9,361.3

4,678.7

4,102.0

Fair Value of Plan Assets

-

-

4,763.8

4,535.2

4,045.0

Funded Status

-

-

-4,597.5

-143.5

-57.0

Total Funded Status

-

-

-5,260.2

-6,124.9

-5,428.1

Discount Rate - Domestic

-

-

5.00%

5.50%

6.00%

Discount Rate - Foreign

-

-

5.03%

5.54%

6.02%

Compensation Rate - Domestic

-

-

2.54%

2.53%

2.50%

Compensation Rate - Foreign

-

-

2.62%

2.63%

2.68%

Pension Increase - Domestic

-

-

2.00%

2.00%

2.00%

Pension Increase - Foreign

-

-

2.06%

2.07%

2.02%

Expected Return on Plan Assets-Domestic

-

-

4.93%

5.00%

5.00%

Expected Return on Plan Assets - Foreign

-

-

5.35%

5.35%

5.41%

Shares

-

-

9.90%

-

-

Debt Securities % - Domestic

-

-

79.70%

-

-

Real Estate % - Domestic

-

-

0.50%

-

-

Other Investments % - Domestic

-

-

9.90%

-

-

 




 

Annual Cash Flows

Financials in: USD (mil)

 

 

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Restated Normal
31-Dec-2012

Updated Normal
31-Dec-2010

Reclassified Normal
31-Dec-2010

Reclassified Normal
31-Dec-2009

Filed Currency

EUR

EUR

EUR

EUR

EUR

Exchange Rate (Period Average)

0.778237

0.71919

0.755078

0.719047

0.683679

Auditor

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers AG

PricewaterhouseCoopers LLP

Auditor Opinion

Unqualified

Unqualified

Unqualified

Unqualified

Unqualified

 

 

 

 

 

 

EBIT - Coninuing Operations

2,411.9

2,554.3

1,773.3

730.1

1,187.7

    Depreciation

1,028.0

1,091.5

1,058.2

1,140.4

1,636.7

    Disposal of Non-Current Assets

-5.1

7.0

-27.8

-20.9

-266.2

    Other Non-Cash Income/Expense

-

-

-

-

49.7

    Change in Inventories

-163.2

-354.6

-237.1

616.1

-634.8

    Change in Receivables/Other Assets

-41.1

-168.2

-327.1

93.2

-318.9

    Change in Payables/Advance Payments

-38.5

105.7

317.8

19.5

275.0

    Change in Provisions

-245.4

-278.1

-233.1

-274.0

-270.6

    Change in Other Provisions

-206.9

-105.7

319.2

-57.0

-5.9

    Change in Assets/Liabilities

-231.3

-150.2

-99.3

91.8

-416.9

    Interest Paid

-208.2

-269.7

-263.5

-308.7

-326.2

    Interest Received

37.3

44.5

45.0

118.2

33.6

    Dividends Paid

84.8

80.6

72.8

69.5

61.4

    Income Taxes Paid

-597.5

-561.7

-317.8

-286.5

-447.6

    Cashflow from Discontinued Operations

0.0

-175.2

667.5

977.7

10.2

Cash from Operating Activities

1,824.6

1,820.1

2,748.1

2,909.4

567.5

 

 

 

 

 

 

    Purchase of Tangib./Intangib./Inv.Prop.

-1,311.9

-1,230.6

-1,018.4

-1,125.1

-1,704.0

    Sale of Tangib./Intangib./Inv. Property

105.4

86.2

70.2

97.4

191.6

    Sale of Business/Equity Investments

-15.4

-

-

-

-

    Acqisition of Business/Equity Investment

-41.1

-186.3

-72.8

-34.8

-122.9

    Sale of Business/Equity Investments

-

1,419.7

83.4

175.2

482.7

    Change in Current Securities & Deposits

-

-

-482.1

8.3

340.8

    Cash inflows/outflows relating to securi

-305.8

-364.3

-

-

-

    Contribution to Pension Taxes

-514.0

-556.2

-264.9

0.0

-

Cash from Investing Activities

-2,082.9

-831.5

-1,684.6

-878.9

-811.8

 

 

 

 

 

 

    Change in Minority Interests

0.0

-4.2

0.0

-

-

    Capital Contributions

39.8

25.0

34.4

11.1

27.8

    Payments to Minority Interest

-14.1

-19.5

-31.8

-84.8

-51.2

    Results from Prev. Year & Dividends Paid

-546.1

-556.2

-423.8

-389.4

-504.6

    Addition of Financial Liabilities

268.6

367.1

470.1

1,705.0

1,437.8

    Repayment of Financial Liabilities

-349.5

-696.6

-548.3

-2,789.8

-389.1

Cash from Financing Activities

-601.4

-884.3

-499.3

-1,547.9

520.7

 

 

 

 

 

 

Foreign Exchange Effects

-1.3

-20.9

53.0

-5.6

5.9

Net Change in Cash

-860.9

83.4

617.2

477.0

282.3

 

 

 

 

 

 

Cash Balance at Beginning of the Year

1,813.1

1,878.5

1,172.1

753.8

510.5

Cash Balance at the End of the Year

952.2

1,961.9

1,789.2

1,230.8

792.8

    Cash Interest Paid

208.2

269.7

263.5

-

326.2

    Cash Taxes Paid

597.5

561.7

317.8

-

447.6

 

 

Financial Health

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

Key Indicators USD (mil)

 

Quarter
Ending
31-Dec-2012

Quarter
Ending
Yr Ago

Annual
Year End
31-Dec-2012

1 Year
Growth

3 Year
Growth

5 Year
Growth

Total Revenue1 (?)

4,246.1

-8.98%

17,512.7

-12.42%

6.23%

-2.31%

Research & Development1 (?)

145.3

16.67%

505.0

7.67%

9.66%

-

Operating Income1 (?)

434.6

23.62%

2,411.9

2.18%

52.91%

14.76%

Income Available to Common Excl Extraord Items1 (?)

358.1

89.04%

1,476.4

5.51%

163.22%

33.20%

Basic EPS Excl Extraord Items1 (?)

0.77

89.05%

3.17

5.51%

163.22%

33.20%

Capital Expenditures2 (?)

1,311.9

15.37%

1,311.9

15.37%

8.07%

-0.90%

Cash from Operating Activities2 (?)

1,824.6

8.48%

1,824.6

8.48%

-12.12%

3.17%

Free Cash Flow (?)

527.4

-5.90%

527.4

-5.90%

-32.25%

22.10%

Total Assets3 (?)

22,023.5

-1.66%

22,023.5

-1.66%

-4.12%

-3.41%

Total Liabilities3 (?)

13,144.3

-9.29%

13,144.3

-9.29%

-11.15%

-8.16%

Total Long Term Debt3 (?)

1,935.0

-46.67%

1,935.0

-46.67%

-28.71%

-17.16%

Total Common Shares Outstanding3 (?)

466.0

0.00%

466.0

0.00%

0.00%

0.00%

1-ExchangeRate: EUR to USD Average for Period

0.770822

 

0.778237

 

 

 

2-ExchangeRate: EUR to USD Average for Period

0.778237

 

0.778237

 

 

 

3-ExchangeRate: EUR to USD Period End Date

0.756600

 

0.756600

 

 

 

Key Ratios

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Profitability

Gross Margin (?)

28.83%

34.09%

33.79%

32.00%

26.74%

Operating Margin (?)

13.77%

11.81%

9.38%

4.62%

4.80%

Pretax Margin (?)

11.83%

9.92%

6.83%

1.66%

2.14%

Net Profit Margin (?)

8.43%

7.00%

5.19%

0.55%

0.97%

Financial Strength

Current Ratio (?)

1.35

1.75

1.52

1.55

1.46

Long Term Debt/Equity (?)

0.22

0.46

0.53

0.85

0.94

Total Debt/Equity (?)

0.44

0.53

0.59

0.95

1.16

Management Effectiveness

Return on Assets (?)

6.86%

5.83%

4.06%

0.69%

1.17%

Return on Equity (?)

18.10%

19.18%

14.67%

1.34%

3.54%

Efficiency

Receivables Turnover (?)

6.40

7.42

6.16

4.01

5.71

Inventory Turnover (?)

5.77

6.34

5.95

4.08

6.19

Asset Turnover (?)

0.81

0.83

0.72

0.58

0.85

Market Valuation USD (mil)

P/E (TTM) (?)

12.61

.

Enterprise Value2 (?)

20,781.9

Price/Sales (TTM) (?)

1.06

.

Enterprise Value/Revenue (TTM) (?)

1.15

Price/Book (MRQ) (?)

2.16

.

Enterprise Value/EBITDA (TTM) (?)

5.87

Market Cap as of 17-May-20131 (?)

18,688.9

.

 

 

1-ExchangeRate: EUR to USD on 17-May-2013

0.775467

 

 

 

2-ExchangeRate: EUR to USD on 31-Dec-2012

0.756600

 

 

 

 

 

 Annual Ratios

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 



 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Financial Strength

Current Ratio (?)

1.35

1.75

1.52

1.55

1.46

Quick/Acid Test Ratio (?)

0.94

1.25

0.57

1.07

0.91

Working Capital1 (?)

1,975.9

3,286.9

4,503.6

2,779.1

2,795.4

Long Term Debt/Equity (?)

0.22

0.46

0.53

0.85

0.94

Total Debt/Equity (?)

0.44

0.53

0.59

0.95

1.16

Long Term Debt/Total Capital (?)

0.15

0.30

0.34

0.44

0.44

Total Debt/Total Capital (?)

0.30

0.34

0.37

0.49

0.54

Payout Ratio (?)

0.00%

38.94%

53.92%

510.36%

0.00%

Effective Tax Rate (?)

28.54%

29.23%

17.95%

28.57%

35.36%

Total Capital1 (?)

12,774.3

11,849.5

11,470.3

13,232.7

14,006.1

 

 

 

 

 

 

Efficiency

Asset Turnover (?)

0.81

0.83

0.72

0.58

0.85

Inventory Turnover (?)

5.77

6.34

5.95

4.08

6.19

Days In Inventory (?)

63.27

57.53

61.38

89.38

58.98

Receivables Turnover (?)

6.40

7.42

6.16

4.01

5.71

Days Receivables Outstanding (?)

57.07

49.19

59.27

91.03

63.95

Revenue/Employee2 (?)

-

-

556,318

421,660

576,383

Operating Income/Employee2 (?)

-

-

52,208

19,473

27,687

EBITDA/Employee2 (?)

-

-

80,789

47,440

54,931

 

 

 

 

 

 

Profitability

Gross Margin (?)

28.83%

34.09%

33.79%

32.00%

26.74%

Operating Margin (?)

13.77%

11.81%

9.38%

4.62%

4.80%

EBITDA Margin (?)

19.64%

15.68%

14.52%

11.25%

9.53%

EBIT Margin (?)

13.77%

11.81%

9.38%

4.62%

4.80%

Pretax Margin (?)

11.83%

9.92%

6.83%

1.66%

2.14%

Net Profit Margin (?)

8.43%

7.00%

5.19%

0.55%

0.97%

R&D Expense/Revenue (?)

2.88%

2.35%

2.37%

2.62%

1.84%

COGS/Revenue (?)

71.17%

65.85%

66.16%

68.00%

73.26%

SG&A Expense/Revenue (?)

13.86%

14.73%

15.87%

23.06%

18.66%

 

 

 

 

 

 

Management Effectiveness

Return on Assets (?)

6.86%

5.83%

4.06%

0.69%

1.17%

Return on Equity (?)

18.10%

19.18%

14.67%

1.34%

3.54%

 

 

 

 

 

 

Valuation

Free Cash Flow/Share2 (?)

1.13

1.18

3.76

3.95

-2.32

Operating Cash Flow/Share 2 (?)

4.03

3.65

5.97

6.44

1.16

1-ExchangeRate: EUR to USD Period End Date

0.7566

0.770327

0.745406

0.696986

0.719399

2-ExchangeRate: EUR to USD Average for Period

0.7566

0.770327

0.745406

0.696986

0.719399

 

Current Market Multiples

Market Cap/Earnings (TTM) (?)

12.61

Market Cap/Equity (MRQ) (?)

2.16

Market Cap/Revenue (TTM) (?)

1.06

Market Cap/EBIT (TTM) (?)

7.62

Market Cap/EBITDA (TTM) (?)

5.36

Enterprise Value/Earnings (TTM) (?)

13.68

Enterprise Value/Equity (MRQ) (?)

2.34

Enterprise Value/Revenue (TTM) (?)

1.15

Enterprise Value/EBIT (TTM) (?)

8.27

Enterprise Value/EBITDA (TTM) (?)

5.82

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.73

UK Pound

1

Rs.99.79

Euro

1

Rs.85.07

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.